<?xml version="1.0" encoding="utf-8" ?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving
and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">

<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.2" article-type="other">

<front>
<journal-meta>
<journal-id></journal-id>

<journal-title-group>
<journal-title>bioRxiv</journal-title>
</journal-title-group>
<issn></issn>

<publisher>
<publisher-name></publisher-name>
</publisher>
</journal-meta>


<article-meta>


<title-group>
<article-title>Virtual Clinical Trials of BMP4 Differentiation Therapy:
Digital Twins to Aid Glioblastoma Trial Design</article-title>
</title-group>

<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">0009-0008-2424-4516</contrib-id>
<name>
<surname>Harbour</surname>
<given-names>Nicholas</given-names>
</name>
<string-name>Nicholas Harbour</string-name>

<email>nicholas.harbour@nottingham.ac.uk</email>
<xref ref-type="aff" rid="aff-1">a</xref>
<xref ref-type="corresp" rid="cor-1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">0000-0002-4083-3803</contrib-id>
<name>
<surname>Curtin</surname>
<given-names>Lee</given-names>
</name>
<string-name>Lee Curtin</string-name>

<xref ref-type="aff" rid="aff-2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hubbard</surname>
<given-names>Matthew E</given-names>
</name>
<string-name>Matthew E Hubbard</string-name>

<xref ref-type="aff" rid="aff-3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jackson</surname>
<given-names>Pamela R.</given-names>
</name>
<string-name>Pamela R. Jackson</string-name>

<xref ref-type="aff" rid="aff-2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rani</surname>
<given-names>Vinitha</given-names>
</name>
<string-name>Vinitha Rani</string-name>

<xref ref-type="aff" rid="aff-4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kenchappa</surname>
<given-names>Rajappa S</given-names>
</name>
<string-name>Rajappa S Kenchappa</string-name>

<xref ref-type="aff" rid="aff-4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Araujo Farias</surname>
<given-names>Virginea</given-names>
</name>
<string-name>Virginea de Araujo Farias</string-name>

<xref ref-type="aff" rid="aff-4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carrano</surname>
<given-names>Anna</given-names>
</name>
<string-name>Anna Carrano</string-name>

<xref ref-type="aff" rid="aff-4">d</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Quinones-Hinojosa</surname>
<given-names>Alfredo</given-names>
</name>
<string-name>Alfredo Quinones-Hinojosa</string-name>

<email>quinones-hinojosa.alfredo@mayo.edu</email>
<xref ref-type="aff" rid="aff-4">d</xref>
<xref ref-type="corresp" rid="cor-9">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">0000-0002-3028-9138</contrib-id>
<name>
<surname>Owen</surname>
<given-names>Markus</given-names>
</name>
<string-name>Markus Owen</string-name>

<email>markus.owen@nottingham.ac.uk</email>
<xref ref-type="aff" rid="aff-1">a</xref>
<xref ref-type="corresp" rid="cor-10">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">0000-0002-2464-6119</contrib-id>
<name>
<surname>Swanson</surname>
<given-names>Kristin R.</given-names>
</name>
<string-name>Kristin R. Swanson</string-name>

<email>swanson.kristin@mayo.edu</email>
<xref ref-type="aff" rid="aff-2">b</xref>
<xref ref-type="corresp" rid="cor-11">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="aff-1">
<institution-wrap>
<institution>Centre for Mathematical Medicine and Biology, School of
Mathematical Sciences, University of Nottingham, Nottingham, NG7 2RD,
UK</institution>
</institution-wrap>







</aff>
<aff id="aff-2">
<institution-wrap>
<institution>Mathematical Neuro-Oncology lab, Mayo Clinic Phoenix, AZ,
85054, USA</institution>
</institution-wrap>







</aff>
<aff id="aff-3">
<institution-wrap>
<institution>School of Mathematical Sciences, University of Nottingham,
University Park, Nottingham, NG7 2RD, UK</institution>
</institution-wrap>







</aff>
<aff id="aff-4">
<institution-wrap>
<institution>Department of Neurosurgery, Mayo Clinic, Jacksonville, FL,
32224, USA</institution>
</institution-wrap>







</aff>
<author-notes>
<corresp id="cor-1">nicholas.harbour@nottingham.ac.uk</corresp>
<corresp id="cor-9">quinones-hinojosa.alfredo@mayo.edu</corresp>
<corresp id="cor-10">markus.owen@nottingham.ac.uk</corresp>
<corresp id="cor-11">swanson.kristin@mayo.edu</corresp>
</author-notes>

<pub-date date-type="pub" publication-format="electronic" iso-8601-date="2024-08-22">
<year>2024</year>
<month>8</month>
<day>22</day>
</pub-date>







<history></history>


<abstract>
<p>We leverage an integrative mathematical modeling framework to
translate the impact of preclinical findings in virtual clinical trials.
We develop a virtual clinical trial pipeline to face the real-world
problem of numerous of actual early phase clinical trials that have
failed for glioma/glioblastoma, the most common primary brain tumor.
Even with the most promising preclinical data, designing clinical trials
is fraught with challenges, including controlling for the many
parameters used to inform patient selection criteria. Here, we introduce
a virtual trial pipeline that allows us to consider the variability from
some of these criteria that can be used for future trials of novel
therapies. As an example, we apply this to the proposed delivery of BMP4
to stem cell niches present in glioblastoma, the most aggressive glioma,
known for its inter- and intra-patient heterogeneity. The proposed
approach of BMP4 treatment, delivered through adipose-derived
mesenchymal stem cells, aims to promote cellular differentiation away
from the treatment-resistance stem cell niches towards a more
treatment-vulnerable state. This pipeline will help us narrow down
strategies for future trials, optimize timing of treatments relative to
key standard-of-care treatments, and predict synergy amongst the
developed treatments.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>Glioblastoma</kwd>
<kwd>Glioma stem cells</kwd>
<kwd>BMP4</kwd>
<kwd>Mathematical oncology</kwd>
<kwd>Virtual clinical trial</kwd>
<kwd>Mathematical modelling</kwd>
<kwd>Digital twin</kwd>
</kwd-group>




</article-meta>

</front>

<body>
<sec id="sec-introduction">
  <title>1. Introduction</title>
  <p>Glioblastoma (GBM) is the most commonly diagnosed primary malignant
  brain cancer in adults. Current standard of care consists of maximal
  safe surgical resection followed by concurrent radiotherapy and
  chemotherapy (with temozolomide)
  (<xref alt="Stupp et al. 2005" rid="ref-stupp2005" ref-type="bibr">Stupp
  et al. 2005</xref>). Despite this aggressive treatment, outcomes
  remain poor with median survival of only 15 months
  (<xref alt="Ostrom et al. 2019" rid="ref-ostrom2019" ref-type="bibr">Ostrom
  et al. 2019</xref>). The aggressiveness and fatal outcomes of GBM can
  be attributed to its highly infiltrative nature and to its vast intra-
  and inter-patient heterogeneity. Malignant cells can be found
  infiltrating far into the peritumoral areas of the brain and are
  undetectable by conventional imaging and operative techniques.
  Furthermore, tumors contain an array of different cell types with
  distinct molecular and phenotypic characteristics, hindering therapy
  efficacy. In particular, previous studies have identified a
  sub-population of malignant glioma cells with stem-like
  characteristics known as glioma stem cells (GSCs) or brain tumor
  initiating cells (BTICs). These cells are highly resistant to both
  radio- and chemo-therapy and therefore contribute to treatment failure
  (<xref alt="Bao et al. 2006" rid="ref-bao2006" ref-type="bibr">Bao et
  al. 2006</xref>;
  <xref alt="Singh et al. 2004" rid="ref-singh2004" ref-type="bibr">Singh
  et al. 2004</xref>). Thus, if treatment outcomes are to be improved
  for patients with GBM, it is vital that therapeutics that specifically
  target these GSCs are developed.</p>
  <p>The existence of a population of cancer stem cells (CSCs) was first
  established in leukemia
  (<xref alt="Lapidot et al. 1994" rid="ref-lapidot1994" ref-type="bibr">Lapidot
  et al. 1994</xref>;
  <xref alt="Bonnet and Dick 1997" rid="ref-bonnet1997" ref-type="bibr">Bonnet
  and Dick 1997</xref>). More recently CSCs have been identified in many
  solid tumors including breast, colon and brain
  (<xref alt="Al-Hajj et al. 2003" rid="ref-al-hajj2003" ref-type="bibr">Al-Hajj
  et al. 2003</xref>;
  <xref alt="Ricci-Vitiani et al. 2007" rid="ref-ricci-vitiani2007" ref-type="bibr">Ricci-Vitiani
  et al. 2007</xref>;
  <xref alt="Ignatova et al. 2002" rid="ref-ignatova2002" ref-type="bibr">Ignatova
  et al. 2002</xref>;
  <xref alt="Hemmati et al. 2003" rid="ref-hemmati2003" ref-type="bibr">Hemmati
  et al. 2003</xref>;
  <xref alt="Singh et al. 2004" rid="ref-singh2004" ref-type="bibr">Singh
  et al. 2004</xref>;
  <xref alt="Galli et al. 2004" rid="ref-galli2004" ref-type="bibr">Galli
  et al. 2004</xref>). In GBM, cells expressing the CD133 cell surface
  protein marker (also found on neural stem cells) have been identified
  as GSCs based on their exclusive ability to commence and support tumor
  growth
  (<xref alt="Singh et al. 2004" rid="ref-singh2004" ref-type="bibr">Singh
  et al. 2004</xref>). In addition to being tumor initiating, GSCs are
  highly resistant to both radio- and chemo-therapy as they are more
  efficient at inducing repair of damaged DNA
  (<xref alt="Bao et al. 2006" rid="ref-bao2006" ref-type="bibr">Bao et
  al. 2006</xref>;
  <xref alt="Tang et al. 2021" rid="ref-tang2021" ref-type="bibr">Tang
  et al. 2021</xref>;
  <xref alt="Rich 2007" rid="ref-rich2007" ref-type="bibr">Rich
  2007</xref>;
  <xref alt="Stiles and Rowitch 2008" rid="ref-stiles2008" ref-type="bibr">Stiles
  and Rowitch 2008</xref>;
  <xref alt="Schonberg et al. 2014" rid="ref-schonberg2014" ref-type="bibr">Schonberg
  et al. 2014</xref>;
  <xref alt="Turner et al. 2009" rid="ref-turner2009" ref-type="bibr">Turner
  et al. 2009</xref>;
  <xref alt="Dirks 2006" rid="ref-dirks2006" ref-type="bibr">Dirks
  2006</xref>). Furthermore, they also engage in a synergistic
  relationship with the surrounding tumor microenvironment (TME) to
  promote angiogenesis, proliferation, migration, tumor survival, and
  immune evasion
  (<xref alt="Ma et al. 2018" rid="ref-ma2018" ref-type="bibr">Ma et al.
  2018</xref>). Under the brain cancer stem cell hypothesis, it is
  becoming increasingly clear that while radiation may be transiently
  effective, treatment ultimately fails in the long run if any GSCs
  survive
  (<xref alt="Dingli and Michor 2006" rid="ref-dingli2006" ref-type="bibr">Dingli
  and Michor 2006</xref>).</p>
  <p>If, as with normal tissues, cellular phenotypic heterogeneity
  within tumors can be explained by a hierarchy of differentiation, with
  only a subset of stem-like cells capable of long-term self-renewal
  (<xref alt="Carén, Beck, and Pollard 2016" rid="ref-carén2016" ref-type="bibr">Carén,
  Beck, and Pollard 2016</xref>), this raises the prospect that signals
  promoting differentiation could be effective at driving malignant
  cells to a less aggressive and ideally post-mitotic differentiated
  state. This differentiation therapy approach has seen success in acute
  promyelocytic leukemia (APL) where all-trans-retinoic acid (ATRA) can
  promote differentiation of CSCs and lead to complete remission
  (<xref alt="De Thé 2018" rid="ref-dethé2018" ref-type="bibr">De Thé
  2018</xref>;
  <xref alt="Yan and Liu 2016" rid="ref-yan2016" ref-type="bibr">Yan and
  Liu 2016</xref>). In GBM, bone morphogenetic protein 4 (BMP4), a
  member of the TGF-<inline-formula><alternatives>
  <tex-math><![CDATA[\beta]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>
  superfamily, has shown potential as a differentiation therapeutic
  agent. BMP4 has been shown to drive differentiation of GSCs towards a
  predominantly glial (astrocytic) fate, to reduce GBM tumor burden
  <italic>in vivo</italic> and to improve survival in a mouse model of
  GBM
  (<xref alt="Nayak et al. 2020" rid="ref-nayak2020" ref-type="bibr">Nayak
  et al. 2020</xref>;
  <xref alt="Carén, Beck, and Pollard 2016" rid="ref-carén2016" ref-type="bibr">Carén,
  Beck, and Pollard 2016</xref>;
  <xref alt="Piccirillo et al. 2006" rid="ref-piccirillo2006" ref-type="bibr">Piccirillo
  et al. 2006</xref>). The precise mechanism through which BMP4 acts is
  unknown but a possible explanation is that it reduces the frequency of
  symmetric divisions of GSCs
  (<xref alt="Guerrero-Cázares et al. 2014" rid="ref-guerrero-cázares2014" ref-type="bibr">Guerrero-Cázares
  et al. 2014</xref>), and previous mathematical models of
  differentiation therapy have assumed that differentiation promoters
  act in this way
  (<xref alt="Youssefpour et al. 2012" rid="ref-youssefpour2012" ref-type="bibr">Youssefpour
  et al. 2012</xref>;
  <xref alt="Bachman and Hillen 2013" rid="ref-bachman2013" ref-type="bibr">Bachman
  and Hillen 2013</xref>).</p>
  <p>Adipose derived mesenchymal stem cells (AMSCs) provide a possible
  alternative to traditional treatment, as these cells preferentially
  migrate toward areas of malignancy, and can be utilized to home
  towards the infiltrating glioma cells
  (<xref alt="Li et al. 2014" rid="ref-li2014" ref-type="bibr">Li et al.
  2014</xref>;
  <xref alt="Mangraviti et al. 2016" rid="ref-mangraviti2016" ref-type="bibr">Mangraviti
  et al. 2016</xref>;
  <xref alt="Pendleton et al. 2013" rid="ref-pendleton2013" ref-type="bibr">Pendleton
  et al. 2013</xref>;
  <xref alt="Smith et al. 2015" rid="ref-smith2015" ref-type="bibr">Smith
  et al. 2015</xref>;
  <xref alt="Doucette et al. 2011" rid="ref-doucette2011" ref-type="bibr">Doucette
  et al. 2011</xref>). Additionally AMSCs can be engineered to secrete
  BMP4 for GBM therapy, and a migration assay showed that compared to
  controls, engineered AMSCs significantly retained their tropism and
  preferential migration towards GBM factors
  (<xref alt="Mangraviti et al. 2016" rid="ref-mangraviti2016" ref-type="bibr">Mangraviti
  et al. 2016</xref>;
  <xref alt="J. Kim et al. 2020" rid="ref-kim2020" ref-type="bibr">J.
  Kim et al. 2020</xref>;
  <xref alt="Guerrero-Cázares et al. 2014" rid="ref-guerrero-cázares2014" ref-type="bibr">Guerrero-Cázares
  et al. 2014</xref>;
  <xref alt="Tzeng et al. 2011" rid="ref-tzeng2011" ref-type="bibr">Tzeng
  et al. 2011</xref>). It has been shown that nanoparticle-engineered
  AMSCs maintain their multi-potency characteristics and release their
  therapeutic cargo progressively, furthermore systemically-delivered
  engineered AMSCs can cross the blood-brain barrier and retain their
  preferential tropism towards gliomas
  (<xref alt="Mangraviti et al. 2016" rid="ref-mangraviti2016" ref-type="bibr">Mangraviti
  et al. 2016</xref>). Therefore, AMSCs delivery promises the ability to
  hone in on GSC niches and locally release treatment to these regions.
  BMP4-loaded AMSCS (BMP4-AMSCs) would theoretically migrate to GSCs,
  release BMP4, and increase the rate of their differentiation, reducing
  the number of GSCs and increasing sensitivity to standard
  treatments.</p>
  <p>Clinical trials typically consist of four phases in which a new
  intervention is investigated in human subjects to determine its safety
  and efficacy. This system is notoriously resource intensive and
  inefficient. The average cost per patient is $59,500 and takes more
  than 10 years, with only 10% of drugs in phase 1 studies eventually
  approved
  (<xref alt="Dowden and Munro 2019" rid="ref-dowden2019" ref-type="bibr">Dowden
  and Munro 2019</xref>;
  <xref alt="Yankeelov et al. 2024" rid="ref-yankeelov2024" ref-type="bibr">Yankeelov
  et al. 2024</xref>). In GBM, the statistics are even worse; multiple
  recent phase 3 trials have failed to meet their prespecified primary
  endpoints
  (<xref alt="Bagley et al. 2022" rid="ref-bagley2022" ref-type="bibr">Bagley
  et al. 2022</xref>;
  <xref alt="Reardon et al. 2020" rid="ref-reardon2020" ref-type="bibr">Reardon
  et al. 2020</xref>;
  <xref alt="Cloughesy et al. 2020" rid="ref-cloughesy2020" ref-type="bibr">Cloughesy
  et al. 2020</xref>;
  <xref alt="Weller et al. 2017" rid="ref-weller2017" ref-type="bibr">Weller
  et al. 2017</xref>;
  <xref alt="Narita et al. 2019" rid="ref-narita2019" ref-type="bibr">Narita
  et al. 2019</xref>;
  <xref alt="Roth et al. 2021" rid="ref-roth2021" ref-type="bibr">Roth
  et al. 2021</xref>). Of course, there are many reasons for these
  failures including inter- and intra-patient variability, drug delivery
  limitations, paucity of control arms, overly stringent clinical
  eligibility, and beyond
  (<xref alt="Bagley et al. 2022" rid="ref-bagley2022" ref-type="bibr">Bagley
  et al. 2022</xref>).</p>
  <p>Increasingly, it is being realised that mathematical modelling and
  <italic>in silico</italic> clinical trials can assist in addressing a
  number of these problems. Subfields such as virtual clinical trials
  (<xref alt="Craig et al. 2023" rid="ref-craig2023" ref-type="bibr">Craig
  et al. 2023</xref>), phase <italic>i</italic> trials
  (<xref alt="E. Kim et al. 2016" rid="ref-kim2016" ref-type="bibr">E.
  Kim et al. 2016</xref>), and digital twins
  (<xref alt="Wu et al. 2022" rid="ref-wu2022" ref-type="bibr">Wu et al.
  2022</xref>) have evolved all with the aim to create simulated
  patients or patient cohorts that can be used as a surrogate to predict
  the effects of treatment on a more personalized level. This approach
  has been applied to a variety of cancers, including breast cancer
  (<xref alt="Wang et al. 2019" rid="ref-wang2019" ref-type="bibr">Wang
  et al. 2019</xref>;
  <xref alt="Wang et al. 2020" rid="ref-wang2020" ref-type="bibr">Wang
  et al. 2020</xref>), head and neck cancer
  (<xref alt="Zahid et al. 2021" rid="ref-zahid2021" ref-type="bibr">Zahid
  et al. 2021</xref>), melanoma
  (<xref alt="E. Kim et al. 2016" rid="ref-kim2016" ref-type="bibr">E.
  Kim et al. 2016</xref>), and ovarian cancer
  (<xref alt="Cardinal et al. 2022" rid="ref-cardinal2022" ref-type="bibr">Cardinal
  et al. 2022</xref>). Here, we take a similar <italic>in
  silico</italic> approach to glioblastoma and its proposed treatment
  with BMP4-AMSCs.</p>
</sec>
<sec id="sec-materials-methods">
  <title>2. Materials and methods</title>
  <p>We use mathematical modelling to simulate GSC-driven brain tumor
  growth. Our model describes the interplay of GSCs
  (<inline-formula><alternatives>
  <tex-math><![CDATA[s(t)]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>)
  and non-GSCs (<inline-formula><alternatives>
  <tex-math><![CDATA[v(t)]]></tex-math>
  <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>v</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>).
  To describe radiation therapy we use the well-established linear
  quadratic model
  (<xref alt="R. Rockne et al. 2009" rid="ref-rockne2009" ref-type="bibr">R.
  Rockne et al. 2009</xref>;
  <xref alt="McMahon 2018" rid="ref-mcmahon2018" ref-type="bibr">McMahon
  2018</xref>) with realistic standard treatments (five treatments per
  week, weekends off, for six weeks) and with tissue-specific
  radiosensitivity parameters. Following
  (<xref alt="Bachman and Hillen 2013" rid="ref-bachman2013" ref-type="bibr">Bachman
  and Hillen 2013</xref>;
  <xref alt="Youssefpour et al. 2012" rid="ref-youssefpour2012" ref-type="bibr">Youssefpour
  et al. 2012</xref>) we model differentiation therapy as decreasing the
  propensity for self-renewal of GSCs.</p>
  <sec id="sec-pre-clinical-data">
    <title>2.1 Pre-clinical data</title>
    <p>To quantify the effect of BMP4 on sensitising GSCs, we used data
    collected from a clonogenic radiotherapy (RT) assay
    (<xref alt="Farias et al., n.d." rid="ref-farias" ref-type="bibr">Farias
    et al., n.d.</xref>). Five GSC cell lines were treated with either
    complete media (untreated control), BMP4 (100 ng/ml), BMP4-AMSCs
    conditioned media (100 ng/ml BMP4), or a similar volume of
    non-engineered AMSC conditioned media for a period of 48 hours, then
    seeded at 250-1250 cells per well in 96 well plates and treated with
    0, 2, 4, 6 Gy of radiation, with six replicates in each case. After
    14 days the colonies with more than 100 nm diameter were manually
    counted.</p>
    <p>Typically, the linear quadratic (LQ) model is used to describe
    the surviving fraction of cells after radiation. However, this
    assumes only one cell type is present
    (<xref alt="R. Rockne et al. 2009" rid="ref-rockne2009" ref-type="bibr">R.
    Rockne et al. 2009</xref>;
    <xref alt="McMahon 2018" rid="ref-mcmahon2018" ref-type="bibr">McMahon
    2018</xref>;
    <xref alt="Yu et al. 2015" rid="ref-yu2015" ref-type="bibr">Yu et
    al. 2015</xref>). In the control case, GSC lines are cultured in
    stem cell media, so we assume that cells will remain as GSCs unless
    any BMP4 or other differentiation promoter is present, thus the LQ
    model is applicable. However, when BMP4 is applied some amount of
    differentiation of GSCs will take place that explains the increased
    sensitivity to RT. To get an estimate for the amount of
    differentiation that took place over 48hr exposure, we fit a
    dual-linear quadratic (DLQ) model similar to that of
    (<xref alt="Yu et al. 2015" rid="ref-yu2015" ref-type="bibr">Yu et
    al. 2015</xref>), given by:</p>
    <p><styled-content id="eq-DLQ"><disp-formula><alternatives>
    <tex-math><![CDATA[
      \gamma(d) = F \text{exp}(\eta(-\alpha d - \beta d^2)) + (1-F)\text{exp}(-\alpha d - \beta d^2)
     \qquad(1)]]></tex-math>
    <mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>γ</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>F</mml:mi><mml:mtext mathvariant="normal">exp</mml:mtext><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>η</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>−</mml:mi><mml:mi>α</mml:mi><mml:mi>d</mml:mi><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:msup><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>F</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mtext mathvariant="normal">exp</mml:mtext><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>−</mml:mi><mml:mi>α</mml:mi><mml:mi>d</mml:mi><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:msup><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mspace width="2.0em"></mml:mspace><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></styled-content></p>
    <p>where <inline-formula><alternatives>
    <tex-math><![CDATA[d]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>d</mml:mi></mml:math></alternatives></inline-formula>
    is the RT dose, <inline-formula><alternatives>
    <tex-math><![CDATA[F]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>F</mml:mi></mml:math></alternatives></inline-formula>
    is the fraction of GSCs and <inline-formula><alternatives>
    <tex-math><![CDATA[\eta]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>η</mml:mi></mml:math></alternatives></inline-formula>
    is the protection factor for GSCs that accounts for the fact that
    GSCs are less sensitive to radiation than other cancer cells;
    previous experiments have estimated GSC radio-protection to be
    <inline-formula><alternatives>
    <tex-math><![CDATA[\eta = 0.1376]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>η</mml:mi><mml:mo>=</mml:mo><mml:mn>0.1376</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>
    (<xref alt="Gao et al. 2013" rid="ref-gao2013" ref-type="bibr">Gao
    et al. 2013</xref>). We infer the radiobiological parameter from the
    cell line data in the following way. First, we assume that since the
    GSC lines are cultured in stem cell media no differentiation will
    take place, therefore we fit the LQ model to the control case for
    each cell line, assuming the ratio <inline-formula><alternatives>
    <tex-math><![CDATA[\alpha / \beta = 10]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>α</mml:mi><mml:mi>/</mml:mi><mml:mi>β</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>
    (<xref alt="R. Rockne et al. 2010" rid="ref-rockne2010" ref-type="bibr">R.
    Rockne et al. 2010</xref>), to get an estimate for
    <inline-formula><alternatives>
    <tex-math><![CDATA[\alpha]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>.
    These form the cell-line-specific radiosensitivity parameters. Using
    these parameters we fit the DLQ model to the BMP4 treated survival
    data, treating <inline-formula><alternatives>
    <tex-math><![CDATA[\alpha]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>
    and <inline-formula><alternatives>
    <tex-math><![CDATA[\beta]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>
    as fixed constants for each cell line from the control case so that
    we are only fitting for <inline-formula><alternatives>
    <tex-math><![CDATA[F]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>F</mml:mi></mml:math></alternatives></inline-formula>.
    This allows us to get an estimate of the fraction of GSCs after
    48hrs exposure to BMP4 in each cell line. The fitted
    <inline-formula><alternatives>
    <tex-math><![CDATA[\alpha]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>
    and <inline-formula><alternatives>
    <tex-math><![CDATA[F]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>F</mml:mi></mml:math></alternatives></inline-formula>
    for all the cell lines are shown in
    <xref alt="Table 1" rid="tbl-RT-data">Table 1</xref>.</p>
  </sec>
  <sec id="sec-model-assumptions">
    <title>2.2 Model assumptions and equations</title>
    <list list-type="bullet">
      <list-item>
        <p>GSCs have unlimited replicative potential.</p>
      </list-item>
      <list-item>
        <p>GSCs are capable of both self-renewing and differentiating.
        Using the same notation as
        (<xref alt="Youssefpour et al. 2012" rid="ref-youssefpour2012" ref-type="bibr">Youssefpour
        et al. 2012</xref>) we denote the proportion of GSCs that
        self-renew by <inline-formula><alternatives>
        <tex-math><![CDATA[P_s]]></tex-math>
        <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula>.
        This does not distinguish between symmetric and asymmetric
        division, but rather just considers the overall fraction of
        proliferating cells that self-renew
        (<inline-formula><alternatives>
        <tex-math><![CDATA[P_s]]></tex-math>
        <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula>)
        and differentiate (<inline-formula><alternatives>
        <tex-math><![CDATA[1 - P_s]]></tex-math>
        <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>).</p>
      </list-item>
      <list-item>
        <p>Progenitor cells (PCs) have a limited replicative potential,
        this ensures that they are not tumor-initiating. Following
        (<xref alt="Enderling, Hlatky, and Hahnfeldt 2009" rid="ref-enderling2009" ref-type="bibr">Enderling,
        Hlatky, and Hahnfeldt 2009</xref>;
        <xref alt="Gao et al. 2013" rid="ref-gao2013" ref-type="bibr">Gao
        et al. 2013</xref>), the proliferative potential of PCs is set
        to a maximum of <inline-formula><alternatives>
        <tex-math><![CDATA[n = 10]]></tex-math>
        <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>
        divisions. Once PCs have divided <inline-formula><alternatives>
        <tex-math><![CDATA[n=10]]></tex-math>
        <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>
        times they become terminally differentiated (TC) and can no
        longer proliferate.</p>
      </list-item>
    </list>
    <p><xref alt="Figure 1" rid="fig-model_schematic">Figure 1</xref>
    shows a schematic of this model. Following these assumptions, we
    derive the following equations,</p>
    <p><styled-content id="eq-gsc-model"><disp-formula><alternatives>
    <tex-math><![CDATA[
    \begin{aligned}
      \underbrace{\frac{d s}{d t}}_{
        \substack{\text{Rate of} \\ \text{change GSCs}}} &=  \underbrace{(2P_s -1)  m_s s \left( 1 - \frac{N}{k}  \right)}_\text{Self-renewal of GSCs} - \underbrace{\delta_{s} s}_\text{Apoptosis}, \\
      \underbrace{\frac{d v_1}{d t}}_{
        \substack{\text{Rate of} \\ \text{change PCs}}} &= \underbrace{2(1- P_s)  m_s s \left( 1 - \frac{N}{k}  \right)}_{
        \substack{\text{Differentiation} \\ \text{of GSCs}}} - \underbrace{m_1 v_1 \left( 1 - \frac{N}{k} \right)}_\text{Proliferation of PCs} - \underbrace{\delta_{1} v_1}_\text{Apoptosis}, \\
      \underbrace{\frac{d v_i}{d t}}_{
        \substack{\text{Rate of} \\ \text{change PCs}}} &= \underbrace{2 m_{i-1} v_{i-1} \left( 1 - \frac{N}{k}  \right)}_{
        \substack{\text{Proliferation of} \\ \text{PCs}}} - \underbrace{m_i v_i \left( 1 - \frac{N}{k} \right)}_\text{Proliferation of PCs} - \underbrace{\delta_{i} v_i}_\text{Apoptosis}, \; i=2,...,n-1 \\
      \underbrace{\frac{d v_n}{d t}}_{
        \substack{\text{Rate of} \\ \text{change PCs}}} &= \underbrace{2 m_{n-1} v_{n-1} \left( 1 - \frac{N}{k}  \right)}_{
        \substack{\text{Differentiation} \\ \text{of PCs}}} - \underbrace{\delta_{n} v_n}_\text{Apoptosis}, \\
    \end{aligned} 
     \qquad(2)]]></tex-math>
    <mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:munder><mml:munder><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtable><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">Rate of</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">change GSCs</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:munder></mml:mtd><mml:mtd columnalign="left" style="text-align: left"><mml:mo>=</mml:mo><mml:munder><mml:munder><mml:mrow><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Self-renewal of GSCs</mml:mtext></mml:munder><mml:mo>−</mml:mo><mml:munder><mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mi>s</mml:mi></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Apoptosis</mml:mtext></mml:munder><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:munder><mml:munder><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>v</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtable><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">Rate of</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">change PCs</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:munder></mml:mtd><mml:mtd columnalign="left" style="text-align: left"><mml:mo>=</mml:mo><mml:munder><mml:munder><mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtable><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">Differentiation</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">of GSCs</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:munder><mml:mo>−</mml:mo><mml:munder><mml:munder><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>v</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Proliferation of PCs</mml:mtext></mml:munder><mml:mo>−</mml:mo><mml:munder><mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>v</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Apoptosis</mml:mtext></mml:munder><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:munder><mml:munder><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtable><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">Rate of</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">change PCs</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:munder></mml:mtd><mml:mtd columnalign="left" style="text-align: left"><mml:mo>=</mml:mo><mml:munder><mml:munder><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtable><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">Proliferation of</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">PCs</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:munder><mml:mo>−</mml:mo><mml:munder><mml:munder><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Proliferation of PCs</mml:mtext></mml:munder><mml:mo>−</mml:mo><mml:munder><mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Apoptosis</mml:mtext></mml:munder><mml:mo>,</mml:mo><mml:mspace width="0.278em"></mml:mspace><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>.</mml:mi><mml:mi>.</mml:mi><mml:mi>.</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:munder><mml:munder><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>v</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtable><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">Rate of</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">change PCs</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:munder></mml:mtd><mml:mtd columnalign="left" style="text-align: left"><mml:mo>=</mml:mo><mml:munder><mml:munder><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:mi>N</mml:mi><mml:mi>k</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtable><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">Differentiation</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">of PCs</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:munder><mml:mo>−</mml:mo><mml:munder><mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:msub><mml:mi>v</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Apoptosis</mml:mtext></mml:munder><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right" style="text-align: right"></mml:mtd></mml:mtr></mml:mtable><mml:mspace width="2.0em"></mml:mspace><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></styled-content></p>
    <p>where <inline-formula><alternatives>
    <tex-math><![CDATA[s(t)]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>s</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
    is the density of GSCs, <inline-formula><alternatives>
    <tex-math><![CDATA[v_i(t)]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
    is the density of PCs (at proliferation level
    <inline-formula><alternatives>
    <tex-math><![CDATA[i]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula>)
    and <inline-formula><alternatives>
    <tex-math><![CDATA[v_n(t)]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
    are terminally differentiated cells. The total density of the tumor
    is given by <inline-formula><alternatives>
    <tex-math><![CDATA[N(t) = s + \sum_{i=1}^{n} v_i]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>.
    The apoptosis rate for GSCs is <inline-formula><alternatives>
    <tex-math><![CDATA[\delta_s]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>δ</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
    and for PCs are given by <inline-formula><alternatives>
    <tex-math><![CDATA[\delta_i]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></alternatives></inline-formula>.
    The proliferation rates of GSCs and PCs are given by
    <inline-formula><alternatives>
    <tex-math><![CDATA[m_s]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>m</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula>,
    <inline-formula><alternatives>
    <tex-math><![CDATA[m_i]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
    respectively, where we assume all <inline-formula><alternatives>
    <tex-math><![CDATA[m_i]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
    are equal. These proliferation rates are subject to a crowding
    response, represented by the term <inline-formula><alternatives>
    <tex-math><![CDATA[1 - N/k]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>N</mml:mi><mml:mi>/</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>
    where <inline-formula><alternatives>
    <tex-math><![CDATA[k]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>k</mml:mi></mml:math></alternatives></inline-formula>
    is the carrying capacity of the tumor.</p>
    <fig id="fig-model_schematic">
      <caption><p>Figure 1: Model schematic, showing how GSCs
      differentiate into progenitor cancer cells which can then divide a
      number of times, doubling in number each time
      (<xref alt="Equation 2" rid="eq-gsc-model">Equation 2</xref>).
      Eventually, PCs become terminally differentiated and are no longer
      able to proliferate. Introduced AMSCs gradually die and release
      BMP4
      (<xref alt="Equation 3" rid="eq-AMSC-BMP4-model">Equation 3</xref>)
      which modifies the self-renewal rate
      <inline-formula><alternatives>
      <tex-math><![CDATA[P_s]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
      according to <xref alt="Equation 4" rid="eq-Ps">Equation 4</xref>.
      (created with BioRender.com)</p></caption>
      <graphic mimetype="image" mime-subtype="png" xlink:href="images/model_schema.png" />
    </fig>
    <sec id="sec-differentiation-therapy">
      <title>2.2.1 Differentiation therapy with mesenchymal stem cell
      delivery model</title>
      <p>A possible delivery mechanism for BMP4 is via AMSCs. These
      could be implanted at the time of resection, or systemically with
      the ability to cross the blood-brain barrier and subsequently
      diffuse with preferential tropism towards glioma cells. We model
      AMSCs as simply decaying exponentially from an initial
      concentration at implantation. BMP4 is released from these AMSCs
      and taken up by GSCs. The equations for both the AMSC and BMP4 are
      thus given by.</p>
      <p><styled-content id="eq-AMSC-BMP4-model"><disp-formula><alternatives>
      <tex-math><![CDATA[
      \begin{aligned}
          \underbrace{\frac{d m}{d t}}_{
          \substack{\text{Rate of} \\ \text{change AMSCs}}} &= \underbrace{-\delta_m m}_\text{Decay of AMSCs} \\ 
          \underbrace{\frac{d B}{d t}}_{
          \substack{\text{Rate of} \\ \text{change BMP4}}} &=  \underbrace{C m}_\text{Release of BMP4} - \underbrace{u_sBs}_\text{uptake by GSCs} - \underbrace{\delta_B B}_\text{Decay of BMP4}, 
      \end{aligned} 
       \qquad(3)]]></tex-math>
      <mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:munder><mml:munder><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtable><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">Rate of</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">change AMSCs</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:munder></mml:mtd><mml:mtd columnalign="left" style="text-align: left"><mml:mo>=</mml:mo><mml:munder><mml:munder><mml:mrow><mml:mi>−</mml:mi><mml:msub><mml:mi>δ</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mi>m</mml:mi></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Decay of AMSCs</mml:mtext></mml:munder></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:munder><mml:munder><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtable><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">Rate of</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center" style="text-align: center"><mml:mtext mathvariant="normal">change BMP4</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:munder></mml:mtd><mml:mtd columnalign="left" style="text-align: left"><mml:mo>=</mml:mo><mml:munder><mml:munder><mml:mrow><mml:mi>C</mml:mi><mml:mi>m</mml:mi></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Release of BMP4</mml:mtext></mml:munder><mml:mo>−</mml:mo><mml:munder><mml:munder><mml:mrow><mml:msub><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mi>B</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">uptake by GSCs</mml:mtext></mml:munder><mml:mo>−</mml:mo><mml:munder><mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi>B</mml:mi></mml:msub><mml:mi>B</mml:mi></mml:mrow><mml:mo accent="true">⏟</mml:mo></mml:munder><mml:mtext mathvariant="normal">Decay of BMP4</mml:mtext></mml:munder><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable><mml:mspace width="2.0em"></mml:mspace><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></styled-content></p>
      <p>where <inline-formula><alternatives>
      <tex-math><![CDATA[\delta_m]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>δ</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
      is the decay rate of AMSCs, <inline-formula><alternatives>
      <tex-math><![CDATA[C]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>C</mml:mi></mml:math></alternatives></inline-formula>
      is the rate at which AMSCs release BMP4,
      <inline-formula><alternatives>
      <tex-math><![CDATA[u_s]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>u</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
      is the uptake rate of BMP4 by GSCs and
      <inline-formula><alternatives>
      <tex-math><![CDATA[\delta_B]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>δ</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
      is the decay rate of BMP4. <italic>In vivo</italic> experiments
      have shown that AMSCs can survive for around 14 days in a rodent
      model and that BMP4 reaches its peak concentration at around 48hrs
      after initial implantation of AMSC
      (<xref alt="Li et al. 2014" rid="ref-li2014" ref-type="bibr">Li et
      al. 2014</xref>).</p>
    </sec>
    <sec id="sec-BMP4-model">
      <title>2.2.2 BMP4 model</title>
      <p>Following
      (<xref alt="Bachman and Hillen 2013" rid="ref-bachman2013" ref-type="bibr">Bachman
      and Hillen 2013</xref>), we model differentiation therapy through
      a simple relationship between the level of differentiation
      promoter (BMP4), and the probability of GSC self-renewal,
      <inline-formula><alternatives>
      <tex-math><![CDATA[P_s]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula>,
      and do not consider the effect of a GSC promoter such as WNT
      (<xref alt="Lee et al. 2016" rid="ref-lee2016" ref-type="bibr">Lee
      et al. 2016</xref>;
      <xref alt="Youssefpour et al. 2012" rid="ref-youssefpour2012" ref-type="bibr">Youssefpour
      et al. 2012</xref>). Therefore, the relationship between
      <inline-formula><alternatives>
      <tex-math><![CDATA[P_s]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
      and BMP4 is given by</p>
      <p><styled-content id="eq-Ps"><disp-formula><alternatives>
      <tex-math><![CDATA[
          P_s(t) = P_\text{min} + (P_\text{max} - P_\text{min})  \left( \frac{1}{1 +  \psi B(t)} \right),
       \qquad(4)]]></tex-math>
      <mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mtext mathvariant="normal">min</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mtext mathvariant="normal">max</mml:mtext></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mtext mathvariant="normal">min</mml:mtext></mml:msub><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>ψ</mml:mi><mml:mi>B</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mspace width="2.0em"></mml:mspace><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>4</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></styled-content></p>
      <p>where <inline-formula><alternatives>
      <tex-math><![CDATA[P_\text{min}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mtext mathvariant="normal">min</mml:mtext></mml:msub></mml:math></alternatives></inline-formula>
      and <inline-formula><alternatives>
      <tex-math><![CDATA[P_\text{max}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mtext mathvariant="normal">max</mml:mtext></mml:msub></mml:math></alternatives></inline-formula>
      are the minimum and maximum self-renewal probabilities and
      <inline-formula><alternatives>
      <tex-math><![CDATA[B(t)]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>B</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
      represents the concentration of BMP4.
      <inline-formula><alternatives>
      <tex-math><![CDATA[P_\text{max}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mtext mathvariant="normal">max</mml:mtext></mml:msub></mml:math></alternatives></inline-formula>
      is attained if there is no BMP4 present, while
      <inline-formula><alternatives>
      <tex-math><![CDATA[P_\text{min}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mtext mathvariant="normal">min</mml:mtext></mml:msub></mml:math></alternatives></inline-formula>
      is approached as <inline-formula><alternatives>
      <tex-math><![CDATA[B \rightarrow \infty]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>B</mml:mi><mml:mo>→</mml:mo><mml:mi>∞</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>.
      We do not consider any endogenous production of BMP4 (or other
      differentiation promoter), therefore it is only present during
      differentiation therapy. The parameter
      <inline-formula><alternatives>
      <tex-math><![CDATA[\psi]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>
      represents the sensitivity of GSCs to BMP4, as
      <inline-formula><alternatives>
      <tex-math><![CDATA[\psi]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>
      increases (for the same concentration of BMP4)
      <inline-formula><alternatives>
      <tex-math><![CDATA[P_\text{min}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mtext mathvariant="normal">min</mml:mtext></mml:msub></mml:math></alternatives></inline-formula>
      is approached faster. Any other potential effects of BMP4, for
      example on growth rates, are ignored as they are in
      (<xref alt="Youssefpour et al. 2012" rid="ref-youssefpour2012" ref-type="bibr">Youssefpour
      et al. 2012</xref>) and
      (<xref alt="Bachman and Hillen 2013" rid="ref-bachman2013" ref-type="bibr">Bachman
      and Hillen 2013</xref>).</p>
    </sec>
    <sec id="sec-RT-model">
      <title>2.2.3 Radiotherapy model</title>
      <p>We model the effects of radiotherapy using the linear quadratic
      (LQ) model, which is widely used in mathematical modelling of RT
      (<xref alt="R. Rockne et al. 2010" rid="ref-rockne2010" ref-type="bibr">R.
      Rockne et al. 2010</xref>;
      <xref alt="R. Rockne et al. 2009" rid="ref-rockne2009" ref-type="bibr">R.
      Rockne et al. 2009</xref>;
      <xref alt="O’Rourke, McAneney, and Hillen 2009" rid="ref-orourke2009" ref-type="bibr">O’Rourke,
      McAneney, and Hillen 2009</xref>;
      <xref alt="McMahon 2018" rid="ref-mcmahon2018" ref-type="bibr">McMahon
      2018</xref>). The fraction of cells that survive,
      <inline-formula><alternatives>
      <tex-math><![CDATA[\gamma_{\text{rad}}(d)]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mtext mathvariant="normal">rad</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
      after a single fractional dose of, <inline-formula><alternatives>
      <tex-math><![CDATA[d]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>d</mml:mi></mml:math></alternatives></inline-formula>
      Grays (Gy) of radiation is given by</p>
      <p><styled-content id="eq-LQ-model"><disp-formula><alternatives>
      <tex-math><![CDATA[
          \gamma_{\text{rad}}(d) = \text{exp}\left(-\eta \mu (\alpha d + \beta d^2)\right),
       \qquad(5)]]></tex-math>
      <mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mtext mathvariant="normal">rad</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mtext mathvariant="normal">exp</mml:mtext><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>−</mml:mi><mml:mi>η</mml:mi><mml:mi>μ</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>α</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msup><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mspace width="2.0em"></mml:mspace><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></styled-content></p>
      <p>where <inline-formula><alternatives>
      <tex-math><![CDATA[\alpha]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>
      can be interpreted as death from single-stranded breaks (linear
      component) and <inline-formula><alternatives>
      <tex-math><![CDATA[\beta]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>β</mml:mi></mml:math></alternatives></inline-formula>
      can be interpreted as death from double-strand breaks (quadratic
      component). It has been shown that the value of
      <inline-formula><alternatives>
      <tex-math><![CDATA[\alpha]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>
      correlates with the proliferation rate of the tumor. We can use
      this linear relationship to estimate
      <inline-formula><alternatives>
      <tex-math><![CDATA[\alpha]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula>
      on a patient-specific level as <inline-formula><alternatives>
      <tex-math><![CDATA[\alpha = 0.05m_v]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mn>0.05</mml:mn><mml:msub><mml:mi>m</mml:mi><mml:mi>v</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>
      (<xref alt="R. Rockne et al. 2010" rid="ref-rockne2010" ref-type="bibr">R.
      Rockne et al. 2010</xref>). To account for the fact that GSCs are
      less sensitive to radiation than other cancer cells, we include
      the additional radio-protection parameter
      <inline-formula><alternatives>
      <tex-math><![CDATA[\eta]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>η</mml:mi></mml:math></alternatives></inline-formula>.
      Previous experiments have estimated GSC radio-protection to be
      <inline-formula><alternatives>
      <tex-math><![CDATA[\eta = 0.1376]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>η</mml:mi><mml:mo>=</mml:mo><mml:mn>0.1376</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>
      (<xref alt="Gao et al. 2013" rid="ref-gao2013" ref-type="bibr">Gao
      et al. 2013</xref>;
      <xref alt="Bao et al. 2006" rid="ref-bao2006" ref-type="bibr">Bao
      et al. 2006</xref>). Additionally, the model contains cells that
      are terminally differentiated and so do not proliferate. RT
      primarily targets actively proliferating cells so is less
      effective against non-proliferating cells. We include
      <inline-formula><alternatives>
      <tex-math><![CDATA[\mu]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>
      to account for this radio-protection of non-proliferating cells,
      previous experiments have found this to be around
      <inline-formula><alternatives>
      <tex-math><![CDATA[\mu = 0.5]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>
      (<xref alt="Gao et al. 2013" rid="ref-gao2013" ref-type="bibr">Gao
      et al. 2013</xref>;
      <xref alt="Griffin 2006" rid="ref-griffin2006" ref-type="bibr">Griffin
      2006</xref>;
      <xref alt="Potten 1981" rid="ref-potten1981" ref-type="bibr">Potten
      1981</xref>).</p>
      <p>It is assumed that all effects of radiation on tumor cell
      density are instantaneous, and no delay or otherwise toxic effects
      of radiotherapy are considered. Nor are any effects on
      proliferation rate as a result of radiotherapy considered.
      Therefore, we model the effects of radiotherapy as an
      instantaneous reduction of tumor density. Considering each
      compartment of the model
      (<xref alt="Equation 2" rid="eq-gsc-model">Equation 2</xref>)
      separately we modify them by</p>
      <p><styled-content id="eq-radiation_model"><disp-formula><alternatives>
      <tex-math><![CDATA[ 
        \begin{aligned}
          s_\text{post-rad} = s_\text{pre-rad} \text{exp}(-\eta(\alpha d + \beta d^2)) \\ 
          v_{i_\text{post-rad}} = v_{i_\text{pre-rad}} \text{exp}(-(\alpha d + \beta d^2)) \\ 
          v_{n_\text{post-rad}} = v_{n_\text{pre-rad}} \text{exp}(-\mu(\alpha d + \beta d^2))
        \end{aligned} 
       \qquad(6)]]></tex-math>
      <mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:msub><mml:mi>s</mml:mi><mml:mtext mathvariant="normal">post-rad</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mtext mathvariant="normal">pre-rad</mml:mtext></mml:msub><mml:mtext mathvariant="normal">exp</mml:mtext><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>−</mml:mi><mml:mi>η</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>α</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msup><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:msub><mml:mi>v</mml:mi><mml:msub><mml:mi>i</mml:mi><mml:mtext mathvariant="normal">post-rad</mml:mtext></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:msub><mml:mi>i</mml:mi><mml:mtext mathvariant="normal">pre-rad</mml:mtext></mml:msub></mml:msub><mml:mtext mathvariant="normal">exp</mml:mtext><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>−</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>α</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msup><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:msub><mml:mi>v</mml:mi><mml:msub><mml:mi>n</mml:mi><mml:mtext mathvariant="normal">post-rad</mml:mtext></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:msub><mml:mi>n</mml:mi><mml:mtext mathvariant="normal">pre-rad</mml:mtext></mml:msub></mml:msub><mml:mtext mathvariant="normal">exp</mml:mtext><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>−</mml:mi><mml:mi>μ</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>α</mml:mi><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msup><mml:mi>d</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mspace width="2.0em"></mml:mspace><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>6</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></styled-content></p>
    </sec>
    <sec id="sec-resection-model">
      <title>2.2.4 Resection model</title>
      <p>Similarly to radiotherapy we model resection as an
      instantaneous loss of density, applied to each model compartment
      separately as</p>
      <p><styled-content id="eq-resection_model"><disp-formula><alternatives>
      <tex-math><![CDATA[
        \begin{aligned}
          s_\text{post-resect} = s_\text{pre-resect} \gamma_\text{res} \\ 
          v_{i,\text{post-resect}} = v_{i,\text{pre-resect}} \gamma_\text{res} \\ 
          v_{n,\text{post-resect}} = v_{n,\text{pre-resect}} \gamma_\text{res},
        \end{aligned} 
       \qquad(7)]]></tex-math>
      <mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:msub><mml:mi>s</mml:mi><mml:mtext mathvariant="normal">post-resect</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mtext mathvariant="normal">pre-resect</mml:mtext></mml:msub><mml:msub><mml:mi>γ</mml:mi><mml:mtext mathvariant="normal">res</mml:mtext></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="normal">post-resect</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="normal">pre-resect</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>γ</mml:mi><mml:mtext mathvariant="normal">res</mml:mtext></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right" style="text-align: right"><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="normal">post-resect</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="normal">pre-resect</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>γ</mml:mi><mml:mtext mathvariant="normal">res</mml:mtext></mml:msub><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable><mml:mspace width="2.0em"></mml:mspace><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>7</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></styled-content></p>
      <p>where <inline-formula><alternatives>
      <tex-math><![CDATA[\gamma_{\text{res}}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>γ</mml:mi><mml:mtext mathvariant="normal">res</mml:mtext></mml:msub></mml:math></alternatives></inline-formula>
      is the surviving fraction after resection. Chaichana et
      al. investigated the efficacy of resection found that on average
      resection resulted in a <inline-formula><alternatives>
      <tex-math><![CDATA[91.7 \%]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mn>91.7</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>
      reduction in tumor volume, so we take
      <inline-formula><alternatives>
      <tex-math><![CDATA[\gamma_{\text{res}} = (1- 0.917)]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mtext mathvariant="normal">res</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>0.917</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
      (<xref alt="Chaichana et al. 2014" rid="ref-chaichana2014" ref-type="bibr">Chaichana
      et al. 2014</xref>).</p>
    </sec>
  </sec>
</sec>
<sec id="sec-results">
  <title>3. Results</title>
  <p>We explore the model for a range of different parameter values to
  help us identify possible strategies for patient selection in early
  phase clinical trials of BMP4 therapy, as well as explore different
  delivery schedules, to increase the likelihood of observing successful
  clinical trials. We parameterise our model to 5 GBM cell lines where
  we have known doubling times, radiotherapy response, and exposure to
  BMP4. This allows us to estimate reasonable values of sensitivity to
  BMP4. We develop a virtual clinical trial pipeline that allows us to
  assess the likelihood of observing a successful trial for different
  patient populations.</p>
  <sec id="sec-simulating-RT-experiments">
    <title>3.1 Simulating radiotherapy experiments</title>
    <p>To parameterise the model we simulate the radiotherapy assay
    described in
    <xref alt="Section 2.1" rid="sec-pre-clinical-data">Section 2.1</xref>.
    In the assay a small number of cells were seeded and allowed to grow
    for 48hrs exposed to either CTRL (GSC media) or BMP4 (100ng/ml) then
    radiotherapy at 0,2,4,6 Gy was applied. The number of surviving
    colonies was then counted. To simulate this we initialise our model
    with a small density of GSCs. The cells are cultured in GSC media in
    the CTRL case so we assume no differentiation takes place before
    treatment (i.e. <inline-formula><alternatives>
    <tex-math><![CDATA[P_s = 1]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>).
    We simulate the BMP4 as a constant concentration for the 48hrs. From
    the DLQ model
    (<xref alt="Equation 1" rid="eq-DLQ">Equation 1</xref>) we have an
    estimate for what the fraction of GSCs should be after the 48hrs and
    given that we also have the doubling time for each cell line we can
    fit the parameter <inline-formula><alternatives>
    <tex-math><![CDATA[\psi]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>,
    which tells us the change in GSC self-renewal
    (<inline-formula><alternatives>
    <tex-math><![CDATA[P_s]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>P</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula>)
    over the 48hrs.</p>
    <p>The fitted <inline-formula><alternatives>
    <tex-math><![CDATA[\psi]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>
    values for each of the 5 cell lines are shown in
    <xref alt="Figure 2 (c)" rid="fig-psi_values_visualised">Figure 2
    (c)</xref> and in
    <xref alt="Table 1" rid="tbl-RT-data">Table 1</xref>. We find that
    each cell line has a distinct sensitivity to BMP4, in agreement with
    work in preparation
    (<xref alt="Farias et al., n.d." rid="ref-farias" ref-type="bibr">Farias
    et al., n.d.</xref>) which shows that GBM1a, QNS657 and QNS120 are
    sensitive to BMP4 while QNS315 and QNS108 are resistant to BMP4
    treatment.</p>
    <fig id="fig-days_gained_example_sim">
      <caption><p>Figure 2: Simulated radiotherapy assay. (a) Initially
      a small number of cells were seeded (represented by a small
      density of tumor cells). These were grown for 2 days under either
      control or 100ng/ml BMP4. After 2 days, radiotherapy was applied
      at different dosages and the number of surviving colonies were
      counted. The red star indicates when RT was applied (48 hrs) and
      the green stars indicate the final measured density of tumor
      immediately after radiotherapy for different doses of radiation.
      (b) Simulated dose response to radiotherapy after fitting
      <inline-formula><alternatives>
      <tex-math><![CDATA[\psi]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>
      in the ODE model to provide the expected fraction of GSCs given
      the doubling time of the cell line. (c) Each of the cell lines has
      a distinct sensitivity to BMP4 denoted
      <inline-formula><alternatives>
      <tex-math><![CDATA[\psi]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>.</p></caption>
      <table-wrap>
        <table>
          <colgroup>
            <col width="50%" />
            <col width="50%" />
          </colgroup>
          <tbody>
            <tr>
              <td align="left"><p specific-use="wrapper">
                <boxed-text>
                  <fig id="fig-sim_RT_assay_GBM1a">
                    <caption><p>(a)</p></caption>
                    <graphic id="fig-sim_RT_assay_GBM1a" mimetype="image" mime-subtype="png" xlink:href="images/png/simulated_RT_assay_GBM1a.png" />
                  </fig>
                </boxed-text>
              </p></td>
              <td align="left"><p specific-use="wrapper">
                <boxed-text>
                  <fig id="fig-sim_dose_response_GBM1a">
                    <caption><p>(b)</p></caption>
                    <graphic id="fig-sim_dose_response_GBM1a" mimetype="image" mime-subtype="png" xlink:href="images/png/simulated_dose_response_GBM1a.png" />
                  </fig>
                </boxed-text>
              </p></td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap>
        <table>
          <colgroup>
            <col width="100%" />
          </colgroup>
          <tbody>
            <tr>
              <td align="left"><p specific-use="wrapper">
                <boxed-text>
                  <fig id="fig-psi_values_visualised">
                    <caption><p>(c)</p></caption>
                    <graphic id="fig-psi_values_visualised" mimetype="image" mime-subtype="png" xlink:href="images/png/psi_values_visualised.png" />
                  </fig>
                </boxed-text>
              </p></td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </fig>
    <fig id="tbl-RT-data">
      <caption><p>Table 1: Fitted parameter values and metadata from
      cell lines. All cell lines are from primary tumor. It is assumed
      that <inline-formula><alternatives>
      <tex-math><![CDATA[\alpha/\beta = 10]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>α</mml:mi><mml:mi>/</mml:mi><mml:mi>β</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>
      is fixed for all cell lines.</p></caption>
      <table-wrap>
        <table>
          <colgroup>
            <col width="17%" />
            <col width="17%" />
            <col width="17%" />
            <col width="17%" />
            <col width="17%" />
            <col width="17%" />
          </colgroup>
          <thead>
            <tr>
              <th>Cell line</th>
              <th><inline-formula><alternatives>
              <tex-math><![CDATA[\alpha]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula></th>
              <th>F</th>
              <th>Doubling time (hrs)</th>
              <th>Sensitivity to BMP4 (<inline-formula><alternatives>
              <tex-math><![CDATA[\psi]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>)</th>
              <th>Sex</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>GBM1a</td>
              <td>0.338</td>
              <td>0.571</td>
              <td>54.7</td>
              <td>0.00850409</td>
              <td>Male</td>
            </tr>
            <tr>
              <td>QNS120</td>
              <td>0.116</td>
              <td>0.770</td>
              <td>43.5</td>
              <td>0.002094342</td>
              <td>Male</td>
            </tr>
            <tr>
              <td>QNS108</td>
              <td>0.151</td>
              <td>0.949</td>
              <td>109</td>
              <td>0.000918066</td>
              <td>Male</td>
            </tr>
            <tr>
              <td>QNS315</td>
              <td>0.0841</td>
              <td>1</td>
              <td>63.6</td>
              <td>0</td>
              <td>Female</td>
            </tr>
            <tr>
              <td>QNS657</td>
              <td>0.104</td>
              <td>0.707</td>
              <td>75.6</td>
              <td>0.006332659</td>
              <td>Female</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </fig>
  </sec>
  <sec id="sec-model-sims">
    <title>3.2 Model simulations</title>
    <p>We simulate our model for a range of parameter values to explore
    the effect of BMP4 on tumor growth. Based on our fitted values of
    <inline-formula><alternatives>
    <tex-math><![CDATA[\psi]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>
    we consider a range from <inline-formula><alternatives>
    <tex-math><![CDATA[[0,0.1]]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mo stretchy="true" form="prefix">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>0.1</mml:mn><mml:mo stretchy="true" form="postfix">]</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>,
    the full parameter values are given in
    <xref alt="Table 2" rid="tbl-params">Table 2</xref>. To simulate
    treatment we allow the model to run until the total tumor size
    reaches <inline-formula><alternatives>
    <tex-math><![CDATA[0.2]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mn>0.2</mml:mn></mml:math></alternatives></inline-formula>,
    then initiate treatment. To evaluate the effect of BMP4, we compare
    two treatment arms: standard of care - resection (at the time of
    detection) followed by radiotherapy 30 days later, and BMP4 -
    standard of care with the addition of BMP4. To observe the effect of
    BMP4, we assume a fixed concentration of AMSCs, which release BMP4
    at a constant rate, from the time of resection until the end of
    radiotherapy. In each case we record the number of days until the
    tumor reaches a size of <inline-formula><alternatives>
    <tex-math><![CDATA[0.6]]></tex-math>
    <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mn>0.6</mml:mn></mml:math></alternatives></inline-formula>
    and refer to this as time to progression. This allows us to
    calculate the fold change in time to progression to directly compare
    for each set of parameters how much the BMP4 prolonged survival. The
    results are shown in
    <xref alt="Figure 3 (b)" rid="fig-days_gained">Figure 3
    (b)</xref>.</p>
    <p>Since GSCs are less sensitive to RT than other cells, the
    fraction of GSCs increases during RT; this is shown in our model in
    <xref alt="Figure 3 (a)" rid="fig-example_sims">Figure 3 (a)</xref>.
    In particular, radiotherapy is more effective against faster
    proliferating tumors
    (<xref alt="R. Rockne et al. 2010" rid="ref-rockne2010" ref-type="bibr">R.
    Rockne et al. 2010</xref>) so this effect is particularly pronounced
    in these tumors. Enrichment of GSCs during RT not only highlights
    that there are some resistant cells not being targeted by
    radiotherapy but also since these are the most tumorigenic cells,
    with a large proportion of GSCs, a recurrent tumor is able to form
    rapidly (as compared to not at all if no GSCs were present). When we
    simulated the addition of BMP4 (the dashed lines in
    <xref alt="Figure 3 (a)" rid="fig-example_sims">Figure 3 (a)</xref>)
    we see that this peak in stem-cell fraction is reduced due to the
    induced differentiation of GSCs. This means that not only is the RT
    more effective as there are fewer resistant GSCs but also that the
    tumor will take longer to recur as there are fewer GSCs to drive
    regrowth. As the increase in GSC fraction is most pronounced in
    faster proliferating tumors, we see that the relative effect of BMP4
    in delaying progression is also largest for these patients.</p>
    <fig id="tbl-params">
      <caption><p>Table 2: Table of parameter values used. When the
      value is fixed its value is given, if it is sampled from a
      distribution then the distribution is given.</p></caption>
      <table-wrap>
        <table>
          <colgroup>
            <col width="20%" />
            <col width="20%" />
            <col width="20%" />
            <col width="20%" />
            <col width="20%" />
          </colgroup>
          <thead>
            <tr>
              <th>Parameter</th>
              <th>Meaning</th>
              <th>Value / distribution</th>
              <th>Units</th>
              <th>Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[\delta_s]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>δ</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula></td>
              <td>death rate of GSCs</td>
              <td>0.001</td>
              <td>1 / year</td>
              <td>Estimated</td>
            </tr>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[\delta_i]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>δ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></alternatives></inline-formula></td>
              <td>death rate of PCs</td>
              <td>0.01</td>
              <td>1 / year</td>
              <td>Estimated</td>
            </tr>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[\delta_n]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>δ</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:math></alternatives></inline-formula></td>
              <td>death rate of TCs</td>
              <td>0.1</td>
              <td>1 / year</td>
              <td>Estimated</td>
            </tr>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[\delta_m]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>δ</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:math></alternatives></inline-formula></td>
              <td>death rate of AMSCs</td>
              <td>0.5</td>
              <td>1 / year</td>
              <td>(<xref alt="Li et al. 2014" rid="ref-li2014" ref-type="bibr">Li
              et al. 2014</xref>)</td>
            </tr>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[\delta_B]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>δ</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:math></alternatives></inline-formula></td>
              <td>Decay rate of BMP4</td>
              <td>0.5</td>
              <td>1 / year</td>
              <td>(<xref alt="Li et al. 2014" rid="ref-li2014" ref-type="bibr">Li
              et al. 2014</xref>)</td>
            </tr>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[u_B]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>u</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:math></alternatives></inline-formula></td>
              <td>Uptake rate of BMP4</td>
              <td>0.5</td>
              <td>1 / year</td>
              <td>Estimated</td>
            </tr>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[C]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>C</mml:mi></mml:math></alternatives></inline-formula></td>
              <td>Release rate of BMP4 from AMSCs</td>
              <td>0.5</td>
              <td>1 / year</td>
              <td>Estimated</td>
            </tr>
            <tr>
              <td>n</td>
              <td>Number of division of PCs</td>
              <td>10</td>
              <td>-</td>
              <td>(<xref alt="Gao et al. 2013" rid="ref-gao2013" ref-type="bibr">Gao
              et al. 2013</xref>)</td>
            </tr>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[m_i]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></alternatives></inline-formula></td>
              <td>Proliferation rate of PCs</td>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[\text{log-N}(2.75,0.51)]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mtext mathvariant="normal">log-N</mml:mtext><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>2.75</mml:mn><mml:mo>,</mml:mo><mml:mn>0.51</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula></td>
              <td>1 / year</td>
              <td>(<xref alt="Yang et al. 2019" rid="ref-yang2019" ref-type="bibr">Yang
              et al. 2019</xref>)</td>
            </tr>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[m_s]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>m</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:math></alternatives></inline-formula></td>
              <td>Proliferation rate of GSCs</td>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[0.0345 m_i]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mn>0.0345</mml:mn><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula></td>
              <td>1 / year</td>
              <td>Estimated</td>
            </tr>
            <tr>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[\alpha]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula></td>
              <td>Radiosensitivity</td>
              <td><inline-formula><alternatives>
              <tex-math><![CDATA[0.05 m_i]]></tex-math>
              <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mn>0.05</mml:mn><mml:msub><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula></td>
              <td>1 / Gy</td>
              <td>(<xref alt="R. Rockne et al. 2010" rid="ref-rockne2010" ref-type="bibr">R.
              Rockne et al. 2010</xref>)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </fig>
    <fig id="fig-effect_BMP4">
      <caption><p>Figure 3: Effect of BMP4 on tumor progression. (a)
      Example model simulations showing the total tumor density and
      fraction of GSCs. Red stars indicate when the tumor was detected
      at <inline-formula><alternatives>
      <tex-math><![CDATA[N=0.2]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>0.2</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>
      and the blue dot represents the start of radiotherapy (30 days
      later). Simulated standard of care (resection and radiotherapy) is
      plotted in solid lines and BMP4-AMSCs is in the dashed lines.
      During radiotherapy the fraction of GSCs is greatly increased as
      they are less sensitive than the non-GSCs. When BMP4 is added this
      enrichment in GSCs is reduced, delaying time for tumor regrowth.
      (b) Days gained surface. As we increase both the sensitivity to
      BMP4 (<inline-formula><alternatives>
      <tex-math><![CDATA[\psi]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>)
      and the proliferation rate the fold change in time to progression
      increases.</p></caption>
      <table-wrap>
        <table>
          <colgroup>
            <col width="50%" />
            <col width="50%" />
          </colgroup>
          <tbody>
            <tr>
              <td align="left"><p specific-use="wrapper">
                <boxed-text>
                  <fig id="fig-example_sims">
                    <caption><p>(a)</p></caption>
                    <graphic id="fig-example_sims" mimetype="image" mime-subtype="png" xlink:href="images/png/example_sims.png" />
                  </fig>
                </boxed-text>
              </p></td>
              <td align="left"><p specific-use="wrapper">
                <boxed-text>
                  <fig id="fig-days_gained">
                    <caption><p>(b)</p></caption>
                    <graphic id="fig-days_gained" mimetype="image" mime-subtype="png" xlink:href="images/png/days_gained.png" />
                  </fig>
                </boxed-text>
              </p></td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </fig>
  </sec>
  <sec id="sec-virtual-trial-pipeline">
    <title>3.3 Virtual clinical trial pipeline</title>
    <p>Firstly we simulate a large cohort of virtual patients with fix
    sensitivity to BMP4 based on the parameters identified in
    <xref alt="Section 3.1" rid="sec-simulating-RT-experiments">Section 3.1</xref>.
    We compare our simulated BMP4 patients to virtual controls to show
    that BMP4 can delay tumor growth. We then develop a pipeline for
    simulating early-phase 2 clinical trials and calculating the
    probability of observing a successful trial.</p>
    <sec id="sec-unce-death-detect">
      <title>3.3.1 Uncertainty in tumor detection and death</title>
      <p>We assume that both detection of the tumor and death depend on
      tumor size in a random fashion for each virtual patient. Detection
      (death) is more likely the bigger a tumor is, but two tumors of
      equal size in two patients do not necessarily lead to detection
      (death) at the same times. Thus, we assume that the times of tumor
      detection and death, represented by the random variables
      <inline-formula><alternatives>
      <tex-math><![CDATA[T_{\text{detect}}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>T</mml:mi><mml:mtext mathvariant="normal">detect</mml:mtext></mml:msub></mml:math></alternatives></inline-formula>
      and <inline-formula><alternatives>
      <tex-math><![CDATA[T_{\text{death}}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>T</mml:mi><mml:mtext mathvariant="normal">death</mml:mtext></mml:msub></mml:math></alternatives></inline-formula>,
      depend on total tumor density <inline-formula><alternatives>
      <tex-math><![CDATA[N(t)]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
      according to the hazard function</p>
      <p><styled-content id="eq-detect_death_hazard"><disp-formula><alternatives>
      <tex-math><![CDATA[
        P(T_d \in [t,t+\Delta t) | T_d>t) = \lambda_d (N(t)) \Delta t + o(\Delta t), \quad d \in \{\text{detect},\text{death}\},
       \qquad(8)]]></tex-math>
      <mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mo>∈</mml:mo><mml:mo stretchy="false" form="prefix">[</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>Δ</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mo>&gt;</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mi>Δ</mml:mi><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi>o</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>Δ</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mspace width="1.0em"></mml:mspace><mml:mi>d</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false" form="prefix">{</mml:mo><mml:mtext mathvariant="normal">detect</mml:mtext><mml:mo>,</mml:mo><mml:mtext mathvariant="normal">death</mml:mtext><mml:mo stretchy="false" form="postfix">}</mml:mo><mml:mo>,</mml:mo><mml:mspace width="2.0em"></mml:mspace><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>8</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></styled-content></p>
      <p>where</p>
      <p><styled-content id="eq-lambda_N"><disp-formula><alternatives>
      <tex-math><![CDATA[
        \lambda_d (N) = \frac{\lambda_{d,\text{max}}}{1 + e^{-m_d(N - N_d)}}.
       \qquad(9)]]></tex-math>
      <mml:math display="block" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="normal">max</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>−</mml:mi><mml:msub><mml:mi>m</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mi>.</mml:mi><mml:mspace width="2.0em"></mml:mspace><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mn>9</mml:mn><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></styled-content></p>
      <p>Here, <inline-formula><alternatives>
      <tex-math><![CDATA[\lambda_d(N)]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>
      is a shifted logistic function; <inline-formula><alternatives>
      <tex-math><![CDATA[\lambda_{d,\text{max}}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="normal">max</mml:mtext></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>
      is the maximum rate of detection that we take to be 1,
      <inline-formula><alternatives>
      <tex-math><![CDATA[m_d]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>m</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
      describes the steepness of the logistic function, which we set to
      be 100 in the detection case and 20 in the death case. The
      constant <inline-formula><alternatives>
      <tex-math><![CDATA[N_d]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mi>N</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:math></alternatives></inline-formula>
      is a threshold parameter at which the probability rate of
      detection or death is half-maximal (each of these for
      <inline-formula><alternatives>
      <tex-math><![CDATA[d\in\{\text{detect},\text{death}\}]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>d</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false" form="prefix">{</mml:mo><mml:mtext mathvariant="normal">detect</mml:mtext><mml:mo>,</mml:mo><mml:mtext mathvariant="normal">death</mml:mtext><mml:mo stretchy="false" form="postfix">}</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>),
      we set this to be 0.2 and 0.7 in the detection and death cases
      respectively. <inline-formula><alternatives>
      <tex-math><![CDATA[\Delta t]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>Δ</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:math></alternatives></inline-formula>
      is the timestep on which the model is solved numerically. This is
      similar to the approach of
      (<xref alt="Bartoszyński et al. 2001" rid="ref-bartoszynski2001" ref-type="bibr">Bartoszyński
      et al. 2001</xref>;
      <xref alt="Plevritis et al. 2006" rid="ref-plevritis2006" ref-type="bibr">Plevritis
      et al. 2006</xref>), apart from our choice of nonlinear dependence
      on tumor size. The shifted logistic function acts as a switch
      mechanism, meaning once <inline-formula><alternatives>
      <tex-math><![CDATA[N > N_d]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>N</mml:mi><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>
      the rate of detection or death rapidly increases towards its
      maximum. <xref alt="Figure 4 (a)" rid="fig-detect_death">Figure 4
      (a)</xref> shows the form of these functions with the parameters
      used in the virtual trials that follow.</p>
    </sec>
    <sec id="sec-simulation-controls">
      <title>3.3.2 Simulated control virtual patient population</title>
      <p>To construct a group of control patients, we sample
      proliferation rates from a distribution consistent with measured
      proliferation rates of around 300 patients
      (<xref alt="Yang et al. 2019" rid="ref-yang2019" ref-type="bibr">Yang
      et al. 2019</xref>), from this distribution we sample 200
      patients. We then simulate these patients undergoing resection and
      radiotherapy (standard of care); to consider the effect of BMP4 on
      survival we assume a constant concentration of 100ng/ml is
      maintained from detection until the end of radiotherapy and we
      consider two different sensitivities
      <inline-formula><alternatives>
      <tex-math><![CDATA[\psi = 0.0021]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>ψ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.0021</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>
      and <inline-formula><alternatives>
      <tex-math><![CDATA[\psi = 0.0085]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>ψ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.0085</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>,
      these values correspond with the cell lines QNS120 and GBM1a from
      <xref alt="Table 1" rid="tbl-RT-data">Table 1</xref>. The results
      are shown in
      <xref alt="Figure 4" rid="fig-simulated-controls">Figure 4</xref>.
      We see that BMP4 improves simulated survival times and that as the
      sensitivity to BMP4 is increased the response is more
      pronounced.</p>
      <fig id="fig-simulated-controls">
        <caption><p>Figure 4: Simulated virtual control patients. (a)
        Tumor detection and death are considered random events which
        increase in probability as tumor size increases. (b) Histogram
        of proliferation rates from
        (<xref alt="Yang et al. 2019" rid="ref-yang2019" ref-type="bibr">Yang
        et al. 2019</xref>), red line shows fitted log normal
        distribution (c) Example model simulation trajectories showing
        overall tumor density and fraction of stem cells. The red stars
        indicate when the tumor was detected and the blue dots when
        radiotherapy was started. (d) Comparison of survival times for
        simulated control patients (resection and radiotherapy) with
        BMP4 treatment, for two different sensitivities to
        BMP4.</p></caption>
        <table-wrap>
          <table>
            <colgroup>
              <col width="50%" />
              <col width="50%" />
            </colgroup>
            <tbody>
              <tr>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-detect_death">
                      <caption><p>(a)</p></caption>
                      <graphic id="fig-detect_death" mimetype="image" mime-subtype="png" xlink:href="images/png/detect_death.png" />
                    </fig>
                  </boxed-text>
                </p></td>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-hist_data">
                      <caption><p>(b)</p></caption>
                      <graphic id="fig-hist_data" mimetype="image" mime-subtype="png" xlink:href="images/png/hist_data.png" />
                    </fig>
                  </boxed-text>
                </p></td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap>
          <table>
            <colgroup>
              <col width="50%" />
              <col width="50%" />
            </colgroup>
            <tbody>
              <tr>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-example_sims_control">
                      <caption><p>(c)</p></caption>
                      <graphic id="fig-example_sims_control" mimetype="image" mime-subtype="png" xlink:href="images/png/sim_control_example_sims.png" />
                    </fig>
                  </boxed-text>
                </p></td>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-simulated_control_KM">
                      <caption><p>(d)</p></caption>
                      <graphic id="fig-simulated_control_KM" mimetype="image" mime-subtype="png" xlink:href="images/png/simulate_control_KM.png" />
                    </fig>
                  </boxed-text>
                </p></td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </fig>
    </sec>
    <sec id="sec-phase-2-trial">
      <title>3.3.3 Simulated phase 2 trial</title>
      <p>In practice a phase 2 trial will have only a small number of
      patients (typically around 20-40) and the population will be
      heterogeneous with respect to sensitivity to BMP4. We develop a
      virtual trial pipeline to consider the chance of observing a
      successful trial for different virtual populations. We have
      previously observed that proliferation rate can impact the
      efficacy of BMP4 treatment
      (<xref alt="Figure 3 (b)" rid="fig-days_gained">Figure 3
      (b)</xref>). Therefore, we consider 3 stratifications of the
      population based on proliferation rate. We construct these by
      sampling twice as many virtual patients as we need for each trial
      (80) and then splitting them into either the top 50% fastest
      proliferators, the middle 50%, or the slowest 50%, so that each
      group has 40 virtual patients. We then split them via a stratified
      random split, so that both groups have similar distributions of
      proliferation rates, into control and treatment arms (20 in each),
      with parameters drawn from
      <xref alt="Table 2" rid="tbl-params">Table 2</xref> and
      <inline-formula><alternatives>
      <tex-math><![CDATA[\psi]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula>
      from a truncated normal distribution. This assumes knowledge of
      growth rates for patients enrolled in the trial, which is
      straightforward for our simulated virtual patients. For each group
      (fast, medium, slow) we perform 20 virtual trials, each one
      comprising a distinct set of 40 patients, giving us an idea of the
      chance of observing a successful trial.</p>
      <p>We assume a distribution of sensitivities drawn from a
      truncated normal distribution with mean sensitivity
      <inline-formula><alternatives>
      <tex-math><![CDATA[\psi_\text{mean} = 0.0085]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mtext mathvariant="normal">mean</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>0.0085</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>,
      so that, according to our model fits this would be a population
      that has been identified as highly sensitive to BMP4. For this
      cohort of virtual patients we consider a possible delivery
      schedule of BMP4-AMSCs which we shall term ‘single-hit’, this
      consists of a single dose of AMSCs-BMP4 at the time of resection.
      This is a promising and practical option for BMP4-AMSCs delivery
      as they can be implanted directly into the tumor at the time of
      resection and means the patient is receiving some treatment in the
      time between resection and radiotherapy, when typically they
      receive none during this time. For this cohort of virtual
      patients, we implement a series of different concentrations of
      AMSCs-BMP4; in
      <xref alt="Figure 5" rid="fig-Identical_mid_KM">Figure 5</xref> we
      show average BMP4 concentration in ng/ml, to compare this to the
      radiotherapy assay in
      <xref alt="Section 3.1" rid="sec-simulating-RT-experiments">Section 3.1</xref>.
      An average concentration of 8ng/ml corresponds to a peak of
      100ng/ml at the time of resection, the same concentration
      maintained for two days in the assay. We see that, for peak
      concentrations of BMP4 similar to that in the <italic>in
      vitro</italic> assay, no trials show statistically significant
      differences in survival curves (log-rank test,
      <inline-formula><alternatives>
      <tex-math><![CDATA[p>0.05]]></tex-math>
      <mml:math display="inline" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>p</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>).
      Indeed, according to these results a considerably higher total
      dose of BMP4 is required in order to see consistently successful
      trials (defined as rejecting the null hypothesis of identical
      survival curves between control and treatment arms). This may be
      because of the relatively rapid decay of AMSCs and BMP4; if ASMCs
      are delivered at the time of resection very few remain and BMP4
      concentrations are low by the time RT begins.</p>
      <p>The results plotted in
      <xref alt="Figure 5" rid="fig-Identical_mid_KM">Figure 5</xref>
      are for the group of fast proliferators only as this was the only
      group which saw a significant response to BMP4 therapy.
      <xref alt="Figure 5 (d)" rid="fig-phase2_trial_summary">Figure 5
      (d)</xref> shows a summary of the results for all the
      proliferation groups. This highlights the importance of
      considering other patient specific parameters when selecting
      potential patients for clinical trial.</p>
      <fig id="fig-Identical_mid_KM">
        <caption><p>Figure 5: Survival curves for 20 simulated virtual
        trials for the fast proliferating stratification shaded by
        success (if BMP4 treatment arm is significantly different to the
        control arm) for four different concentrations of BMP4. (a) As
        expected, when BMP4 is low the control and treatment arms are
        similar in all 20 trials. (b) As BMP4 concentration increases,
        the fraction of successful trials increases. (c) For
        sufficiently high BMP4 (and hence a sufficiently strong
        treatment effect), almost all trials are successful. (d) Summary
        of the successful trial from phase 2. Orange, green and blue
        represent fast, medium and slow proliferation,
        respectively.</p></caption>
        <table-wrap>
          <table>
            <colgroup>
              <col width="50%" />
              <col width="50%" />
            </colgroup>
            <tbody>
              <tr>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-example2">
                      <caption><p>(a)</p></caption>
                      <graphic id="fig-example2" mimetype="image" mime-subtype="png" xlink:href="images/png/virtual_trial_BMP4_200_rho_case_5.png" />
                    </fig>
                  </boxed-text>
                </p></td>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-example3">
                      <caption><p>(b)</p></caption>
                      <graphic id="fig-example3" mimetype="image" mime-subtype="png" xlink:href="images/png/virtual_trial_BMP4_500_rho_case_5.png" />
                    </fig>
                  </boxed-text>
                </p></td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <table-wrap>
          <table>
            <colgroup>
              <col width="50%" />
              <col width="50%" />
            </colgroup>
            <tbody>
              <tr>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-ex-4">
                      <caption><p>(c)</p></caption>
                      <graphic id="fig-ex-4" mimetype="image" mime-subtype="png" xlink:href="images/png/virtual_trial_BMP4_1000_rho_case_5.png" />
                    </fig>
                  </boxed-text>
                </p></td>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-phase2_trial_summary">
                      <caption><p>(d)</p></caption>
                      <graphic id="fig-phase2_trial_summary" mimetype="image" mime-subtype="png" xlink:href="images/png/prob_succ_strat.png" />
                    </fig>
                  </boxed-text>
                </p></td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </fig>
    </sec>
    <sec id="different-delivery-schedules-for-bmp4">
      <title>3.3.4 Different delivery schedules for BMP4</title>
      <p>The high concentrations of BMP4 required in a single-hit
      approach identified in
      <xref alt="Section 3.3.3" rid="sec-phase-2-trial">Section 3.3.3</xref>
      motivates us to look at alternative dosing strategies, where
      similar or greater benefit may be observed for less average dose
      of BMP4. As the AMSCs only last for around 2 weeks (and BMP4
      slightly less) only a small concentration is left by the time
      radiotherapy occurs in the single-hit approach. Since BMP4
      increases the radiosensitivity of the tumor and reduces the
      enrichment of GSCs when radiotherapy occurs, delivering it in
      combination with radiotherapy may provide significantly improved
      responses even when a similar total dose of BMP4 is considered.
      Therefore, we consider 3 alternative treatment schedules: i) a
      single dose immediately before radiotherapy, ii) a continuous dose
      from resection until the end of RT and iii) periodic doses in
      combination with radiotherapy. These schedules are shown in
      <xref alt="Figure 6 (a)" rid="fig-delivery_schedule">Figure 6
      (a)</xref>. In all cases, the same total dose of BMP4 (this
      corresponds to the same area under the curve in
      <xref alt="Figure 6 (a)" rid="fig-delivery_schedule">Figure 6
      (a)</xref>) will be administered so the comparison is fair between
      delivery schedules.</p>
      <p>We use the same virtual trial pipeline outlined previously in
      <xref alt="Section 3.3" rid="sec-virtual-trial-pipeline">Section 3.3</xref>,
      applied to these three alternative dosing strategies. A summary of
      the results for the fast proliferating group is plotted in
      <xref alt="Figure 6 (b)" rid="fig-delivery_schedule_frac_succ">Figure 6
      (b)</xref>. We see that the continuous delivery schedule is the
      most effective, with the highest number of successful trials with
      an average BMP4 concentration of around 10ng/ml required for
      almost all trials to be successful. This is closely followed by
      the periodic schedule. The shifted single dose appears to be
      largely similar in efficacy as the single dose at resection. These
      show that longer term exposure of BMP4 greatly increases its
      efficacy. This highlights the importance of designing the delivery
      schedule of BMP4 to maximise the effect of the treatment, and in
      future could be optimised on a patient-specific level.</p>
      <fig id="fig-delivery_schedule_frac_succ_overall">
        <caption><p>Figure 6: Alternative delivery schedules have
        improved response to BPM4 for same total dose. (a) Different
        delivery schedules for BMP4. Here time 0 represents the time of
        detection and radiotherapy occurs 30 days after detection. (b)
        Summary of fraction of successful trails for different delivery
        schedules.</p></caption>
        <table-wrap>
          <table>
            <colgroup>
              <col width="50%" />
              <col width="50%" />
            </colgroup>
            <tbody>
              <tr>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-delivery_schedule">
                      <caption><p>(a)</p></caption>
                      <graphic id="fig-delivery_schedule" mimetype="image" mime-subtype="png" xlink:href="images/png/BMP4_delivery_schedule.png" />
                    </fig>
                  </boxed-text>
                </p></td>
                <td align="left"><p specific-use="wrapper">
                  <boxed-text>
                    <fig id="fig-delivery_schedule_frac_succ">
                      <caption><p>(b)</p></caption>
                      <graphic id="fig-delivery_schedule_frac_succ" mimetype="image" mime-subtype="png" xlink:href="images/png/diff_schedules_frac_succ.png" />
                    </fig>
                  </boxed-text>
                </p></td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </fig>
    </sec>
  </sec>
</sec>
<sec id="sec-discussion">
  <title>4. Discussion</title>
  <p>In this study, we have developed a comprehensive mathematical model
  to simulate GSC-driven tumor growth, specifically focusing on the
  impact of BMP4 treatment. By parameterizing our model using
  experimental data from five distinct glioma stem cell lines exposed to
  BMP4, we were able to qualitatively estimate the sensitivity of these
  cell lines to BMP4. This approach provides valuable insights into the
  potential variability in treatment response among different glioma
  cell populations.</p>
  <p>A key limitation of our model lies in the inherent assumptions
  necessary for reducing the complex biology of glioblastoma/glioma to a
  system of ordinary differential equations (ODEs). While our model
  successfully encapsulates many aspects of tumor dynamics, it does not
  explicitly account for the spatial heterogeneity of glioblastoma.
  Future work could expand this model to incorporate spatial
  considerations, to better capture the intricate microenvironment and
  its influence on tumor behaviour. That said, we hope that capturing
  the essence of the proposed BMP4 treatment in the current model has
  highlighted key mechanisms by which impact on tumor growth may or may
  not be seen in the clinic.</p>
  <p>Moreover, our study primarily concentrated on the impact of
  BMP4-induced differentiation on radiosensitivity, leaving the direct
  effects of BMP4 on proliferation rates as an area for further
  exploration. Understanding how BMP4 modulates proliferation, in
  addition to differentiation, could provide a more comprehensive
  picture of its therapeutic potential and guide the development of more
  effective treatment strategies.</p>
  <p>Importantly, we have also demonstrated a virtual clinical trial
  pipeline to evaluate the potential of BMP4-AMSCs treatment for
  patients with GBM. Our simulations revealed that a significant amount
  of BMP4 would be required to achieve successful outcomes in a
  substantial proportion of patients. This finding underscores the
  importance of optimizing BMP4 dosage and delivery methods for future
  clinical applications. Additionally, our results suggest that patient
  stratification based on proliferation rates could enhance the
  likelihood of treatment success. By selecting patients with higher
  proliferation rates, we could potentially increase the observed
  efficacy of BMP4 in combination with radiotherapy.</p>
  <p>Furthermore, we explored various BMP4 delivery schedules and
  identified that alternative strategies could enhance the therapeutic
  synergy between BMP4 and radiotherapy. These findings indicate that
  the timing and duration of BMP4 administration, in particular in
  relation to the timing of radiotherapy, can be crucial factors that
  could be optimized to improve clinical outcomes. We have shown that
  prolonged exposure to BMP4 greatly increased it efficacy when compared
  to a ‘single-hit’ approach. Future studies could expand on this by
  investigating different delivery modalities and schedules, potentially
  in combination with other therapies, to maximize the therapeutic
  benefit of BMP4.</p>
  <p>In conclusion, our work provides a robust framework for virtual
  clinical trials, offering valuable predictions that can guide the
  clinical translation of BMP4-based therapies for GBM. By highlighting
  the need for high BMP4 levels, patient stratification, and optimized
  delivery strategies, we have laid the groundwork for future studies
  that can further refine and validate these approaches in a clinical
  context.</p>
</sec>
</body>

<back>
<ref-list>
  <title>References</title>
  <ref id="ref-singh2004">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Singh</surname><given-names>Sheila K.</given-names></name>
        <name><surname>Hawkins</surname><given-names>Cynthia</given-names></name>
        <name><surname>Clarke</surname><given-names>Ian D.</given-names></name>
        <name><surname>Squire</surname><given-names>Jeremy A.</given-names></name>
        <name><surname>Bayani</surname><given-names>Jane</given-names></name>
        <name><surname>Hide</surname><given-names>Takuichiro</given-names></name>
        <name><surname>Henkelman</surname><given-names>R. Mark</given-names></name>
        <name><surname>Cusimano</surname><given-names>Michael D.</given-names></name>
        <name><surname>Dirks</surname><given-names>Peter B.</given-names></name>
      </person-group>
      <article-title>Identification of human brain tumour initiating cells</article-title>
      <source>Nature</source>
      <year iso-8601-date="2004-11">2004</year><month>11</month>
      <volume>432</volume>
      <issue>7015</issue>
      <uri>https://www.nature.com/articles/nature03128</uri>
      <pub-id pub-id-type="doi">10.1038/nature03128</pub-id>
      <fpage>396</fpage>
      <lpage>401</lpage>
    </element-citation>
  </ref>
  <ref id="ref-stupp2005">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Stupp</surname><given-names>Roger</given-names></name>
        <name><surname>Mason</surname><given-names>Warren P.</given-names></name>
        <name><surname>Van Den Bent</surname><given-names>Martin J.</given-names></name>
        <name><surname>Weller</surname><given-names>Michael</given-names></name>
        <name><surname>Fisher</surname><given-names>Barbara</given-names></name>
        <name><surname>Taphoorn</surname><given-names>Martin J. B.</given-names></name>
        <name><surname>Belanger</surname><given-names>Karl</given-names></name>
        <name><surname>Brandes</surname><given-names>Alba A.</given-names></name>
        <name><surname>Marosi</surname><given-names>Christine</given-names></name>
        <name><surname>Bogdahn</surname><given-names>Ulrich</given-names></name>
        <name><surname>Curschmann</surname><given-names>Jürgen</given-names></name>
        <name><surname>Janzer</surname><given-names>Robert C.</given-names></name>
        <name><surname>Ludwin</surname><given-names>Samuel K.</given-names></name>
        <name><surname>Gorlia</surname><given-names>Thierry</given-names></name>
        <name><surname>Allgeier</surname><given-names>Anouk</given-names></name>
        <name><surname>Lacombe</surname><given-names>Denis</given-names></name>
        <name><surname>Cairncross</surname><given-names>J. Gregory</given-names></name>
        <name><surname>Eisenhauer</surname><given-names>Elizabeth</given-names></name>
        <name><surname>Mirimanoff</surname><given-names>René O.</given-names></name>
      </person-group>
      <article-title>Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma</article-title>
      <source>New England Journal of Medicine</source>
      <year iso-8601-date="2005-03-10">2005</year><month>03</month><day>10</day>
      <volume>352</volume>
      <issue>10</issue>
      <uri>http://www.nejm.org/doi/abs/10.1056/NEJMoa043330</uri>
      <pub-id pub-id-type="doi">10.1056/NEJMoa043330</pub-id>
      <fpage>987</fpage>
      <lpage>996</lpage>
    </element-citation>
  </ref>
  <ref id="ref-ostrom2019">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Ostrom</surname><given-names>Quinn T</given-names></name>
        <name><surname>Cioffi</surname><given-names>Gino</given-names></name>
        <name><surname>Gittleman</surname><given-names>Haley</given-names></name>
        <name><surname>Patil</surname><given-names>Nirav</given-names></name>
        <name><surname>Waite</surname><given-names>Kristin</given-names></name>
        <name><surname>Kruchko</surname><given-names>Carol</given-names></name>
        <name><surname>Barnholtz-Sloan</surname><given-names>Jill S</given-names></name>
      </person-group>
      <article-title>CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 20122016</article-title>
      <source>Neuro-Oncology</source>
      <year iso-8601-date="2019-11-01">2019</year><month>11</month><day>01</day>
      <volume>21</volume>
      <issue>Supplement_5</issue>
      <uri>https://academic.oup.com/neuro-oncology/article/21/Supplement_5/v1/5610892</uri>
      <pub-id pub-id-type="doi">10.1093/neuonc/noz150</pub-id>
      <fpage>v1</fpage>
      <lpage>v100</lpage>
    </element-citation>
  </ref>
  <ref id="ref-turner2009">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Turner</surname><given-names>C.</given-names></name>
        <name><surname>Stinchcombe</surname><given-names>A. R.</given-names></name>
        <name><surname>Kohandel</surname><given-names>M.</given-names></name>
        <name><surname>Singh</surname><given-names>S.</given-names></name>
        <name><surname>Sivaloganathan</surname><given-names>S.</given-names></name>
      </person-group>
      <article-title>Characterization of brain cancer stem cells: a mathematical approach</article-title>
      <source>Cell Proliferation</source>
      <year iso-8601-date="2009-08">2009</year><month>08</month>
      <volume>42</volume>
      <issue>4</issue>
      <uri>https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2184.2009.00619.x</uri>
      <pub-id pub-id-type="doi">10.1111/j.1365-2184.2009.00619.x</pub-id>
      <fpage>529</fpage>
      <lpage>540</lpage>
    </element-citation>
  </ref>
  <ref id="ref-dirks2006">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Dirks</surname><given-names>Peter B.</given-names></name>
      </person-group>
      <article-title>Stem cells and brain tumours</article-title>
      <source>Nature</source>
      <year iso-8601-date="2006-12">2006</year><month>12</month>
      <volume>444</volume>
      <issue>7120</issue>
      <uri>https://www.nature.com/articles/444687a</uri>
      <pub-id pub-id-type="doi">10.1038/444687a</pub-id>
      <fpage>687</fpage>
      <lpage>688</lpage>
    </element-citation>
  </ref>
  <ref id="ref-youssefpour2012">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Youssefpour</surname><given-names>H.</given-names></name>
        <name><surname>Li</surname><given-names>X.</given-names></name>
        <name><surname>Lander</surname><given-names>A. D.</given-names></name>
        <name><surname>Lowengrub</surname><given-names>J. S.</given-names></name>
      </person-group>
      <article-title>Multispecies model of cell lineages and feedback control in solid tumors</article-title>
      <source>Journal of Theoretical Biology</source>
      <year iso-8601-date="2012-07">2012</year><month>07</month>
      <volume>304</volume>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S0022519312001154</uri>
      <pub-id pub-id-type="doi">10.1016/j.jtbi.2012.02.030</pub-id>
      <fpage>39</fpage>
      <lpage>59</lpage>
    </element-citation>
  </ref>
  <ref id="ref-rockne2009">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Rockne</surname><given-names>R.</given-names></name>
        <name><surname>Alvord</surname><given-names>E. C.</given-names></name>
        <name><surname>Rockhill</surname><given-names>J. K.</given-names></name>
        <name><surname>Swanson</surname><given-names>K. R.</given-names></name>
      </person-group>
      <article-title>A mathematical model for brain tumor response to radiation therapy</article-title>
      <source>Journal of Mathematical Biology</source>
      <year iso-8601-date="2009-04">2009</year><month>04</month>
      <volume>58</volume>
      <issue>4-5</issue>
      <uri>http://link.springer.com/10.1007/s00285-008-0219-6</uri>
      <pub-id pub-id-type="doi">10.1007/s00285-008-0219-6</pub-id>
      <fpage>561</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-rockne2010">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Rockne</surname><given-names>R</given-names></name>
        <name><surname>Rockhill</surname><given-names>J K</given-names></name>
        <name><surname>Mrugala</surname><given-names>M</given-names></name>
        <name><surname>Spence</surname><given-names>A M</given-names></name>
        <name><surname>Kalet</surname><given-names>I</given-names></name>
        <name><surname>Hendrickson</surname><given-names>K</given-names></name>
        <name><surname>Lai</surname><given-names>A</given-names></name>
        <name><surname>Cloughesy</surname><given-names>T</given-names></name>
        <name><surname>Alvord</surname><given-names>E C</given-names></name>
        <name><surname>Swanson</surname><given-names>K R</given-names></name>
      </person-group>
      <article-title>Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: A mathematical modeling approach</article-title>
      <source>Physics in Medicine and Biology</source>
      <year iso-8601-date="2010-06-21">2010</year><month>06</month><day>21</day>
      <volume>55</volume>
      <issue>12</issue>
      <uri>https://iopscience.iop.org/article/10.1088/0031-9155/55/12/001</uri>
      <pub-id pub-id-type="doi">10.1088/0031-9155/55/12/001</pub-id>
      <fpage>3271</fpage>
      <lpage>3285</lpage>
    </element-citation>
  </ref>
  <ref id="ref-gao2013">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Gao</surname><given-names>Xuefeng</given-names></name>
        <name><surname>McDonald</surname><given-names>J. Tyson</given-names></name>
        <name><surname>Hlatky</surname><given-names>Lynn</given-names></name>
        <name><surname>Enderling</surname><given-names>Heiko</given-names></name>
      </person-group>
      <article-title>Acute and Fractionated Irradiation Differentially Modulate Glioma Stem Cell Division Kinetics</article-title>
      <source>Cancer Research</source>
      <year iso-8601-date="2013-03-01">2013</year><month>03</month><day>01</day>
      <volume>73</volume>
      <issue>5</issue>
      <uri>https://aacrjournals.org/cancerres/article/73/5/1481/586464/Acute-and-Fractionated-Irradiation-Differentially</uri>
      <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3429</pub-id>
      <fpage>1481</fpage>
      <lpage>1490</lpage>
    </element-citation>
  </ref>
  <ref id="ref-dowden2019">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Dowden</surname><given-names>Helen</given-names></name>
        <name><surname>Munro</surname><given-names>Jamie</given-names></name>
      </person-group>
      <article-title>Trends in clinical success rates and therapeutic focus</article-title>
      <source>Nature Reviews Drug Discovery</source>
      <year iso-8601-date="2019-07">2019</year><month>07</month>
      <volume>18</volume>
      <issue>7</issue>
      <uri>https://www.nature.com/articles/d41573-019-00074-z</uri>
      <pub-id pub-id-type="doi">10.1038/d41573-019-00074-z</pub-id>
      <fpage>495</fpage>
      <lpage>496</lpage>
    </element-citation>
  </ref>
  <ref id="ref-yankeelov2024">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Yankeelov</surname><given-names>Thomas E.</given-names></name>
        <name><surname>Hormuth</surname><given-names>David A.</given-names></name>
        <name><surname>Lima</surname><given-names>Ernesto A. B. F.</given-names></name>
        <name><surname>Lorenzo</surname><given-names>Guillermo</given-names></name>
        <name><surname>Wu</surname><given-names>Chengyue</given-names></name>
        <name><surname>Okereke</surname><given-names>Lois C.</given-names></name>
        <name><surname>Rauch</surname><given-names>Gaiane M.</given-names></name>
        <name><surname>Venkatesan</surname><given-names>Aradhana M.</given-names></name>
        <name><surname>Chung</surname><given-names>Caroline</given-names></name>
      </person-group>
      <article-title>Designing clinical trials for patients who are not average</article-title>
      <source>iScience</source>
      <year iso-8601-date="2024-01">2024</year><month>01</month>
      <volume>27</volume>
      <issue>1</issue>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S2589004223026664</uri>
      <pub-id pub-id-type="doi">10.1016/j.isci.2023.108589</pub-id>
      <fpage>108589</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-bagley2022">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Bagley</surname><given-names>Stephen J.</given-names></name>
        <name><surname>Kothari</surname><given-names>Shawn</given-names></name>
        <name><surname>Rahman</surname><given-names>Rifaquat</given-names></name>
        <name><surname>Lee</surname><given-names>Eudocia Q.</given-names></name>
        <name><surname>Dunn</surname><given-names>Gavin P.</given-names></name>
        <name><surname>Galanis</surname><given-names>Evanthia</given-names></name>
        <name><surname>Chang</surname><given-names>Susan M.</given-names></name>
        <name><surname>Nabors</surname><given-names>Louis Burt</given-names></name>
        <name><surname>Ahluwalia</surname><given-names>Manmeet S.</given-names></name>
        <name><surname>Stupp</surname><given-names>Roger</given-names></name>
        <name><surname>Mehta</surname><given-names>Minesh P.</given-names></name>
        <name><surname>Reardon</surname><given-names>David A.</given-names></name>
        <name><surname>Grossman</surname><given-names>Stuart A.</given-names></name>
        <name><surname>Sulman</surname><given-names>Erik P.</given-names></name>
        <name><surname>Sampson</surname><given-names>John H.</given-names></name>
        <name><surname>Khagi</surname><given-names>Simon</given-names></name>
        <name><surname>Weller</surname><given-names>Michael</given-names></name>
        <name><surname>Cloughesy</surname><given-names>Timothy F.</given-names></name>
        <name><surname>Wen</surname><given-names>Patrick Y.</given-names></name>
        <name><surname>Khasraw</surname><given-names>Mustafa</given-names></name>
      </person-group>
      <article-title>Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement</article-title>
      <source>Clinical Cancer Research</source>
      <year iso-8601-date="2022-02-15">2022</year><month>02</month><day>15</day>
      <volume>28</volume>
      <issue>4</issue>
      <uri>https://aacrjournals.org/clincancerres/article/28/4/594/678102/Glioblastoma-Clinical-Trials-Current-Landscape-and</uri>
      <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-2750</pub-id>
      <fpage>594</fpage>
      <lpage>602</lpage>
    </element-citation>
  </ref>
  <ref id="ref-reardon2020">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Reardon</surname><given-names>David A.</given-names></name>
        <name><surname>Brandes</surname><given-names>Alba A.</given-names></name>
        <name><surname>Omuro</surname><given-names>Antonio</given-names></name>
        <name><surname>Mulholland</surname><given-names>Paul</given-names></name>
        <name><surname>Lim</surname><given-names>Michael</given-names></name>
        <name><surname>Wick</surname><given-names>Antje</given-names></name>
        <name><surname>Baehring</surname><given-names>Joachim</given-names></name>
        <name><surname>Ahluwalia</surname><given-names>Manmeet S.</given-names></name>
        <name><surname>Roth</surname><given-names>Patrick</given-names></name>
        <name><surname>Bähr</surname><given-names>Oliver</given-names></name>
        <name><surname>Phuphanich</surname><given-names>Surasak</given-names></name>
        <name><surname>Sepulveda</surname><given-names>Juan Manuel</given-names></name>
        <name><surname>De Souza</surname><given-names>Paul</given-names></name>
        <name><surname>Sahebjam</surname><given-names>Solmaz</given-names></name>
        <name><surname>Carleton</surname><given-names>Michael</given-names></name>
        <name><surname>Tatsuoka</surname><given-names>Kay</given-names></name>
        <name><surname>Taitt</surname><given-names>Corina</given-names></name>
        <name><surname>Zwirtes</surname><given-names>Ricardo</given-names></name>
        <name><surname>Sampson</surname><given-names>John</given-names></name>
        <name><surname>Weller</surname><given-names>Michael</given-names></name>
      </person-group>
      <article-title>Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial</article-title>
      <source>JAMA Oncology</source>
      <year iso-8601-date="2020-07-01">2020</year><month>07</month><day>01</day>
      <volume>6</volume>
      <issue>7</issue>
      <uri>https://jamanetwork.com/journals/jamaoncology/fullarticle/2766213</uri>
      <pub-id pub-id-type="doi">10.1001/jamaoncol.2020.1024</pub-id>
      <fpage>1003</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-cloughesy2020">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Cloughesy</surname><given-names>Timothy F.</given-names></name>
        <name><surname>Petrecca</surname><given-names>Kevin</given-names></name>
        <name><surname>Walbert</surname><given-names>Tobias</given-names></name>
        <name><surname>Butowski</surname><given-names>Nicholas</given-names></name>
        <name><surname>Salacz</surname><given-names>Michael</given-names></name>
        <name><surname>Perry</surname><given-names>James</given-names></name>
        <name><surname>Damek</surname><given-names>Denise</given-names></name>
        <name><surname>Bota</surname><given-names>Daniela</given-names></name>
        <name><surname>Bettegowda</surname><given-names>Chetan</given-names></name>
        <name><surname>Zhu</surname><given-names>Jay-Jiguang</given-names></name>
        <name><surname>Iwamoto</surname><given-names>Fabio</given-names></name>
        <name><surname>Placantonakis</surname><given-names>Dimitris</given-names></name>
        <name><surname>Kim</surname><given-names>Lyndon</given-names></name>
        <name><surname>Elder</surname><given-names>Brad</given-names></name>
        <name><surname>Kaptain</surname><given-names>George</given-names></name>
        <name><surname>Cachia</surname><given-names>David</given-names></name>
        <name><surname>Moshel</surname><given-names>Yaron</given-names></name>
        <name><surname>Brem</surname><given-names>Steven</given-names></name>
        <name><surname>Piccioni</surname><given-names>David</given-names></name>
        <name><surname>Landolfi</surname><given-names>Joseph</given-names></name>
        <name><surname>Chen</surname><given-names>Clark C.</given-names></name>
        <name><surname>Gruber</surname><given-names>Harry</given-names></name>
        <name><surname>Rao</surname><given-names>Aliz R.</given-names></name>
        <name><surname>Hogan</surname><given-names>Daniel</given-names></name>
        <name><surname>Accomando</surname><given-names>William</given-names></name>
        <name><surname>Ostertag</surname><given-names>Derek</given-names></name>
        <name><surname>Montellano</surname><given-names>Tiffany T.</given-names></name>
        <name><surname>Kheoh</surname><given-names>Thian</given-names></name>
        <name><surname>Kabbinavar</surname><given-names>Fairooz</given-names></name>
        <name><surname>Vogelbaum</surname><given-names>Michael A.</given-names></name>
      </person-group>
      <article-title>Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial</article-title>
      <source>JAMA Oncology</source>
      <year iso-8601-date="2020-12-01">2020</year><month>12</month><day>01</day>
      <volume>6</volume>
      <issue>12</issue>
      <uri>https://jamanetwork.com/journals/jamaoncology/fullarticle/2772174</uri>
      <pub-id pub-id-type="doi">10.1001/jamaoncol.2020.3161</pub-id>
      <fpage>1939</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-weller2017">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Weller</surname><given-names>Michael</given-names></name>
        <name><surname>Butowski</surname><given-names>Nicholas</given-names></name>
        <name><surname>Tran</surname><given-names>David D</given-names></name>
        <name><surname>Recht</surname><given-names>Lawrence D</given-names></name>
        <name><surname>Lim</surname><given-names>Michael</given-names></name>
        <name><surname>Hirte</surname><given-names>Hal</given-names></name>
        <name><surname>Ashby</surname><given-names>Lynn</given-names></name>
        <name><surname>Mechtler</surname><given-names>Laszlo</given-names></name>
        <name><surname>Goldlust</surname><given-names>Samuel A</given-names></name>
        <name><surname>Iwamoto</surname><given-names>Fabio</given-names></name>
        <name><surname>Drappatz</surname><given-names>Jan</given-names></name>
        <name><surname>O’Rourke</surname><given-names>Donald M</given-names></name>
        <name><surname>Wong</surname><given-names>Mark</given-names></name>
        <name><surname>Hamilton</surname><given-names>Mark G</given-names></name>
        <name><surname>Finocchiaro</surname><given-names>Gaetano</given-names></name>
        <name><surname>Perry</surname><given-names>James</given-names></name>
        <name><surname>Wick</surname><given-names>Wolfgang</given-names></name>
        <name><surname>Green</surname><given-names>Jennifer</given-names></name>
        <name><surname>He</surname><given-names>Yi</given-names></name>
        <name><surname>Turner</surname><given-names>Christopher D</given-names></name>
        <name><surname>Yellin</surname><given-names>Michael J</given-names></name>
        <name><surname>Keler</surname><given-names>Tibor</given-names></name>
        <name><surname>Davis</surname><given-names>Thomas A</given-names></name>
        <name><surname>Stupp</surname><given-names>Roger</given-names></name>
        <name><surname>Sampson</surname><given-names>John H</given-names></name>
        <name><surname>Butowski</surname><given-names>Nicholas</given-names></name>
        <name><surname>Campian</surname><given-names>Jian</given-names></name>
        <name><surname>Recht</surname><given-names>Lawrence</given-names></name>
        <name><surname>Lim</surname><given-names>Michael</given-names></name>
        <name><surname>Ashby</surname><given-names>Lynn</given-names></name>
        <name><surname>Drappatz</surname><given-names>Jan</given-names></name>
        <name><surname>Hirte</surname><given-names>Hal</given-names></name>
        <name><surname>Iwamoto</surname><given-names>Fabio</given-names></name>
        <name><surname>Mechtler</surname><given-names>Laszlo</given-names></name>
        <name><surname>Goldlust</surname><given-names>Samuel</given-names></name>
        <name><surname>Becker</surname><given-names>Kevin</given-names></name>
        <name><surname>Barnett</surname><given-names>Gene</given-names></name>
        <name><surname>Nicholas</surname><given-names>Garth</given-names></name>
        <name><surname>Desjardins</surname><given-names>Annick</given-names></name>
        <name><surname>Benkers</surname><given-names>Tara</given-names></name>
        <name><surname>Wagle</surname><given-names>Naveed</given-names></name>
        <name><surname>Groves</surname><given-names>Morris</given-names></name>
        <name><surname>Kesari</surname><given-names>Santosh</given-names></name>
        <name><surname>Horvath</surname><given-names>Zsolt</given-names></name>
        <name><surname>Merrell</surname><given-names>Ryan</given-names></name>
        <name><surname>Curry</surname><given-names>Richard</given-names></name>
        <name><surname>O’Rourke</surname><given-names>James</given-names></name>
        <name><surname>Schuster</surname><given-names>David</given-names></name>
        <name><surname>Wong</surname><given-names>Mark</given-names></name>
        <name><surname>Mrugala</surname><given-names>Maciej</given-names></name>
        <name><surname>Jensen</surname><given-names>Randy</given-names></name>
        <name><surname>Trusheim</surname><given-names>John</given-names></name>
        <name><surname>Lesser</surname><given-names>Glenn</given-names></name>
        <name><surname>Belanger</surname><given-names>Karl</given-names></name>
        <name><surname>Sloan</surname><given-names>Andrew</given-names></name>
        <name><surname>Purow</surname><given-names>Benjamin</given-names></name>
        <name><surname>Fink</surname><given-names>Karen</given-names></name>
        <name><surname>Raizer</surname><given-names>Jeffrey</given-names></name>
        <name><surname>Schulder</surname><given-names>Michael</given-names></name>
        <name><surname>Nair</surname><given-names>Suresh</given-names></name>
        <name><surname>Peak</surname><given-names>Scott</given-names></name>
        <name><surname>Perry</surname><given-names>James</given-names></name>
        <name><surname>Brandes</surname><given-names>Alba</given-names></name>
        <name><surname>Weller</surname><given-names>Michael</given-names></name>
        <name><surname>Mohile</surname><given-names>Nimish</given-names></name>
        <name><surname>Landolfi</surname><given-names>Joseph</given-names></name>
        <name><surname>Olson</surname><given-names>Jon</given-names></name>
        <name><surname>Finocchiaro</surname><given-names>Gaetano</given-names></name>
        <name><surname>Jennens</surname><given-names>Ross</given-names></name>
        <name><surname>DeSouza</surname><given-names>Paul</given-names></name>
        <name><surname>Robinson</surname><given-names>Bridget</given-names></name>
        <name><surname>Crittenden</surname><given-names>Marka</given-names></name>
        <name><surname>Shih</surname><given-names>Kent</given-names></name>
        <name><surname>Flowers</surname><given-names>Alexandra</given-names></name>
        <name><surname>Ong</surname><given-names>Shirley</given-names></name>
        <name><surname>Connelly</surname><given-names>Jennifer</given-names></name>
        <name><surname>Hadjipanayis</surname><given-names>Costas</given-names></name>
        <name><surname>Giglio</surname><given-names>Pierre</given-names></name>
        <name><surname>Mott</surname><given-names>Frank</given-names></name>
        <name><surname>Mathieu</surname><given-names>David</given-names></name>
        <name><surname>Lessard</surname><given-names>Nathalie</given-names></name>
        <name><surname>Sepulveda</surname><given-names>Sanchez Juan</given-names></name>
        <name><surname>Lövey</surname><given-names>József</given-names></name>
        <name><surname>Wheeler</surname><given-names>Helen</given-names></name>
        <name><surname>Inglis</surname><given-names>Po-Ling</given-names></name>
        <name><surname>Hardie</surname><given-names>Claire</given-names></name>
        <name><surname>Bota</surname><given-names>Daniela</given-names></name>
        <name><surname>Lesniak</surname><given-names>Maciej</given-names></name>
        <name><surname>Portnow</surname><given-names>Jana</given-names></name>
        <name><surname>Frankel</surname><given-names>Bruce</given-names></name>
        <name><surname>Junck</surname><given-names>Larry</given-names></name>
        <name><surname>Thompson</surname><given-names>Reid</given-names></name>
        <name><surname>Berk</surname><given-names>Lawrence</given-names></name>
        <name><surname>McGhie</surname><given-names>John</given-names></name>
        <name><surname>Macdonald</surname><given-names>David</given-names></name>
        <name><surname>Saran</surname><given-names>Frank</given-names></name>
        <name><surname>Soffietti</surname><given-names>Riccardo</given-names></name>
        <name><surname>Blumenthal</surname><given-names>Deborah</given-names></name>
        <name><surname>André De</surname><given-names>Sá Barreto Costa Marcos</given-names></name>
        <name><surname>Nowak</surname><given-names>Anna</given-names></name>
        <name><surname>Singhal</surname><given-names>Nimit</given-names></name>
        <name><surname>Hottinger</surname><given-names>Andreas</given-names></name>
        <name><surname>Schmid</surname><given-names>Andrea</given-names></name>
        <name><surname>Srkalovic</surname><given-names>Gordan</given-names></name>
        <name><surname>Baskin</surname><given-names>David</given-names></name>
        <name><surname>Fadul</surname><given-names>Camilo</given-names></name>
        <name><surname>Nabors</surname><given-names>Louis</given-names></name>
        <name><surname>LaRocca</surname><given-names>Renato</given-names></name>
        <name><surname>Villano</surname><given-names>John</given-names></name>
        <name><surname>Paleologos</surname><given-names>Nina</given-names></name>
        <name><surname>Kavan</surname><given-names>Petr</given-names></name>
        <name><surname>Pitz</surname><given-names>Marshall</given-names></name>
        <name><surname>Thiessen</surname><given-names>Brian</given-names></name>
        <name><surname>Idbaih</surname><given-names>Ahmed</given-names></name>
        <name><surname>Frenel</surname><given-names>Jean Sébastien</given-names></name>
        <name><surname>Domont</surname><given-names>Julien</given-names></name>
        <name><surname>Grauer</surname><given-names>Oliver</given-names></name>
        <name><surname>Hau</surname><given-names>Peter</given-names></name>
        <name><surname>Marosi</surname><given-names>Christine</given-names></name>
        <name><surname>Sroubek</surname><given-names>Jan</given-names></name>
        <name><surname>Hovey</surname><given-names>Elizabeth</given-names></name>
        <name><surname>Sridhar</surname><given-names>P. S.</given-names></name>
        <name><surname>Cher</surname><given-names>Lawrence</given-names></name>
        <name><surname>Dunbar</surname><given-names>Erin</given-names></name>
        <name><surname>Coyle</surname><given-names>Thomas</given-names></name>
        <name><surname>Raymond</surname><given-names>Jane</given-names></name>
        <name><surname>Barton</surname><given-names>Kevin</given-names></name>
        <name><surname>Guarino</surname><given-names>Michael</given-names></name>
        <name><surname>Raval</surname><given-names>Sumul</given-names></name>
        <name><surname>Stea</surname><given-names>Baldassarre</given-names></name>
        <name><surname>Dietrich</surname><given-names>Jorge</given-names></name>
        <name><surname>Hopkins</surname><given-names>Kirsten</given-names></name>
        <name><surname>Erridge</surname><given-names>Sara</given-names></name>
        <name><surname>Steinbach</surname><given-names>Joachim-Peter</given-names></name>
        <name><surname>Pineda</surname><given-names>Losada Estela</given-names></name>
        <name><surname>Balana</surname><given-names>Quintero Carmen</given-names></name>
        <name><surname>Sonia Del</surname><given-names>Barco Berron</given-names></name>
        <name><surname>Wenczl</surname><given-names>Miklós</given-names></name>
        <name><surname>Molnár</surname><given-names>Katalin</given-names></name>
        <name><surname>Hideghéty</surname><given-names>Katalin</given-names></name>
        <name><surname>Lossos</surname><given-names>Alexander</given-names></name>
        <name><surname>Myra Van</surname><given-names>Linde</given-names></name>
        <name><surname>Levy</surname><given-names>Ana</given-names></name>
        <name><surname>Harrup</surname><given-names>Rosemary</given-names></name>
        <name><surname>Patterson</surname><given-names>William</given-names></name>
        <name><surname>Lwin</surname><given-names>Zarnie</given-names></name>
        <name><surname>Sathornsumetee</surname><given-names>Sith</given-names></name>
        <name><surname>Lee</surname><given-names>E-Jian</given-names></name>
        <name><surname>Ho</surname><given-names>Jih-Tsun</given-names></name>
        <name><surname>Emmons</surname><given-names>Steven</given-names></name>
        <name><surname>Duic</surname><given-names>J. Paul</given-names></name>
        <name><surname>Shao</surname><given-names>Spencer</given-names></name>
        <name><surname>Ashamalla</surname><given-names>Hani</given-names></name>
        <name><surname>Weaver</surname><given-names>Michael</given-names></name>
        <name><surname>Lutzky</surname><given-names>Jose</given-names></name>
        <name><surname>Avgeropoulos</surname><given-names>Nicholas</given-names></name>
        <name><surname>Hanna</surname><given-names>Wahid</given-names></name>
        <name><surname>Nadipuram</surname><given-names>Mukund</given-names></name>
        <name><surname>Cecchi</surname><given-names>Gary</given-names></name>
        <name><surname>O’Donnell</surname><given-names>Robert</given-names></name>
        <name><surname>Pannullo</surname><given-names>Susan</given-names></name>
        <name><surname>Carney</surname><given-names>Jennifer</given-names></name>
        <name><surname>Hamilton</surname><given-names>Mark</given-names></name>
        <name><surname>MacNeil</surname><given-names>Mary</given-names></name>
        <name><surname>Beaney</surname><given-names>Ronald</given-names></name>
        <name><surname>Fabbro</surname><given-names>Michel</given-names></name>
        <name><surname>Schnell</surname><given-names>Oliver</given-names></name>
        <name><surname>Fietkau</surname><given-names>Rainer</given-names></name>
        <name><surname>Stockhammer</surname><given-names>Guenther</given-names></name>
        <name><surname>Malinova</surname><given-names>Bela</given-names></name>
        <name><surname>Odrazka</surname><given-names>Karel</given-names></name>
        <name><surname>Sames</surname><given-names>Martin</given-names></name>
        <name><surname>Miguel Gil</surname><given-names>Gil</given-names></name>
        <name><surname>Razis</surname><given-names>Evangelia</given-names></name>
        <name><surname>Lavrenkov</surname><given-names>Konstantin</given-names></name>
        <name><surname>Castro</surname><given-names>Guillermo</given-names></name>
        <name><surname>Ramirez</surname><given-names>Francisco</given-names></name>
        <name><surname>Baldotto</surname><given-names>Clarissa</given-names></name>
        <name><surname>Viola</surname><given-names>Fabiana</given-names></name>
        <name><surname>Malheiros</surname><given-names>Suzana</given-names></name>
        <name><surname>Lickliter</surname><given-names>Jason</given-names></name>
        <name><surname>Gauden</surname><given-names>Stanislaw</given-names></name>
        <name><surname>Dechaphunkul</surname><given-names>Arunee</given-names></name>
        <name><surname>Thaipisuttikul</surname><given-names>Iyavut</given-names></name>
        <name><surname>Thotathil</surname><given-names>Ziad</given-names></name>
        <name><surname>Ma</surname><given-names>Hsin-I</given-names></name>
        <name><surname>Cheng</surname><given-names>Wen-Yu</given-names></name>
        <name><surname>Chang</surname><given-names>Chin-Hong</given-names></name>
        <name><surname>Salas</surname><given-names>Fernando</given-names></name>
        <name><surname>Dietrich</surname><given-names>Pierre-Yves</given-names></name>
        <name><surname>Mamot</surname><given-names>Christoph</given-names></name>
        <name><surname>Nayak</surname><given-names>Lakshmi</given-names></name>
        <name><surname>Nag</surname><given-names>Shona</given-names></name>
      </person-group>
      <article-title>Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial</article-title>
      <source>The Lancet Oncology</source>
      <year iso-8601-date="2017-10">2017</year><month>10</month>
      <volume>18</volume>
      <issue>10</issue>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S147020451730517X</uri>
      <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30517-X</pub-id>
      <fpage>1373</fpage>
      <lpage>1385</lpage>
    </element-citation>
  </ref>
  <ref id="ref-narita2019">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Narita</surname><given-names>Yoshitaka</given-names></name>
        <name><surname>Arakawa</surname><given-names>Yoshiki</given-names></name>
        <name><surname>Yamasaki</surname><given-names>Fumiyuki</given-names></name>
        <name><surname>Nishikawa</surname><given-names>Ryo</given-names></name>
        <name><surname>Aoki</surname><given-names>Tomokazu</given-names></name>
        <name><surname>Kanamori</surname><given-names>Masayuki</given-names></name>
        <name><surname>Nagane</surname><given-names>Motoo</given-names></name>
        <name><surname>Kumabe</surname><given-names>Toshihiro</given-names></name>
        <name><surname>Hirose</surname><given-names>Yuichi</given-names></name>
        <name><surname>Ichikawa</surname><given-names>Tomotsugu</given-names></name>
        <name><surname>Kobayashi</surname><given-names>Hiroyuki</given-names></name>
        <name><surname>Fujimaki</surname><given-names>Takamitsu</given-names></name>
        <name><surname>Goto</surname><given-names>Hisaharu</given-names></name>
        <name><surname>Takeshima</surname><given-names>Hideo</given-names></name>
        <name><surname>Ueba</surname><given-names>Tetsuya</given-names></name>
        <name><surname>Abe</surname><given-names>Hiroshi</given-names></name>
        <name><surname>Tamiya</surname><given-names>Takashi</given-names></name>
        <name><surname>Sonoda</surname><given-names>Yukihiko</given-names></name>
        <name><surname>Natsume</surname><given-names>Atsushi</given-names></name>
        <name><surname>Kakuma</surname><given-names>Tatsuyuki</given-names></name>
        <name><surname>Sugita</surname><given-names>Yasuo</given-names></name>
        <name><surname>Komatsu</surname><given-names>Nobukazu</given-names></name>
        <name><surname>Yamada</surname><given-names>Akira</given-names></name>
        <name><surname>Sasada</surname><given-names>Tetsuro</given-names></name>
        <name><surname>Matsueda</surname><given-names>Satoko</given-names></name>
        <name><surname>Shichijo</surname><given-names>Shigeki</given-names></name>
        <name><surname>Itoh</surname><given-names>Kyogo</given-names></name>
        <name><surname>Terasaki</surname><given-names>Mizuhiko</given-names></name>
      </person-group>
      <article-title>A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma</article-title>
      <source>Neuro-Oncology</source>
      <year iso-8601-date="2019-02-19">2019</year><month>02</month><day>19</day>
      <volume>21</volume>
      <issue>3</issue>
      <uri>https://academic.oup.com/neuro-oncology/article/21/3/348/5219198</uri>
      <pub-id pub-id-type="doi">10.1093/neuonc/noy200</pub-id>
      <fpage>348</fpage>
      <lpage>359</lpage>
    </element-citation>
  </ref>
  <ref id="ref-roth2021">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Roth</surname><given-names>Patrick</given-names></name>
        <name><surname>Gorlia</surname><given-names>Thierry</given-names></name>
        <name><surname>Reijneveld</surname><given-names>Jaap C.</given-names></name>
        <name><surname>De Vos</surname><given-names>Filip Yves Francine Leon</given-names></name>
        <name><surname>Idbaih</surname><given-names>Ahmed</given-names></name>
        <name><surname>Frenel</surname><given-names>Jean-Sebastien</given-names></name>
        <name><surname>Le Rhun</surname><given-names>Emilie</given-names></name>
        <name><surname>Sepulveda Sánchez</surname><given-names>José Manuel</given-names></name>
        <name><surname>Perry</surname><given-names>James R.</given-names></name>
        <name><surname>Masucci</surname><given-names>Laura</given-names></name>
        <name><surname>Freres</surname><given-names>Pierre</given-names></name>
        <name><surname>Hirte</surname><given-names>Hal W.</given-names></name>
        <name><surname>Seidel</surname><given-names>Clemens</given-names></name>
        <name><surname>Walenkamp</surname><given-names>Anna Maria Elisabeth</given-names></name>
        <name><surname>Dhermain</surname><given-names>Frederic</given-names></name>
        <name><surname>Van Den Bent</surname><given-names>Martin J.</given-names></name>
        <name><surname>O’Callaghan</surname><given-names>Christopher J.</given-names></name>
        <name><surname>Vanlancker</surname><given-names>Maureen</given-names></name>
        <name><surname>Mason</surname><given-names>Warren P.</given-names></name>
        <name><surname>Weller</surname><given-names>Michael</given-names></name>
      </person-group>
      <article-title>EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.</article-title>
      <source>Journal of Clinical Oncology</source>
      <year iso-8601-date="2021-05-20">2021</year><month>05</month><day>20</day>
      <volume>39</volume>
      <issue>15_suppl</issue>
      <uri>https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.2004</uri>
      <pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.2004</pub-id>
      <fpage>2004</fpage>
      <lpage>2004</lpage>
    </element-citation>
  </ref>
  <ref id="ref-enderling2009">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Enderling</surname><given-names>H</given-names></name>
        <name><surname>Hlatky</surname><given-names>L</given-names></name>
        <name><surname>Hahnfeldt</surname><given-names>P</given-names></name>
      </person-group>
      <article-title>Migration rules: tumours are conglomerates of self-metastases</article-title>
      <source>British Journal of Cancer</source>
      <year iso-8601-date="2009-06">2009</year><month>06</month>
      <volume>100</volume>
      <issue>12</issue>
      <uri>https://www.nature.com/articles/6605071</uri>
      <pub-id pub-id-type="doi">10.1038/sj.bjc.6605071</pub-id>
      <fpage>1917</fpage>
      <lpage>1925</lpage>
    </element-citation>
  </ref>
  <ref id="ref-piccirillo2006">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Piccirillo</surname><given-names>S. G. M.</given-names></name>
        <name><surname>Reynolds</surname><given-names>B. A.</given-names></name>
        <name><surname>Zanetti</surname><given-names>N.</given-names></name>
        <name><surname>Lamorte</surname><given-names>G.</given-names></name>
        <name><surname>Binda</surname><given-names>E.</given-names></name>
        <name><surname>Broggi</surname><given-names>G.</given-names></name>
        <name><surname>Brem</surname><given-names>H.</given-names></name>
        <name><surname>Olivi</surname><given-names>A.</given-names></name>
        <name><surname>Dimeco</surname><given-names>F.</given-names></name>
        <name><surname>Vescovi</surname><given-names>A. L.</given-names></name>
      </person-group>
      <article-title>Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells</article-title>
      <source>Nature</source>
      <year iso-8601-date="2006-12">2006</year><month>12</month>
      <volume>444</volume>
      <issue>7120</issue>
      <uri>https://www.nature.com/articles/nature05349</uri>
      <pub-id pub-id-type="doi">10.1038/nature05349</pub-id>
      <fpage>761</fpage>
      <lpage>765</lpage>
    </element-citation>
  </ref>
  <ref id="ref-mangraviti2016">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Mangraviti</surname><given-names>Antonella</given-names></name>
        <name><surname>Tzeng</surname><given-names>Stephany Y.</given-names></name>
        <name><surname>Gullotti</surname><given-names>David</given-names></name>
        <name><surname>Kozielski</surname><given-names>Kristen L.</given-names></name>
        <name><surname>Kim</surname><given-names>Jennifer E.</given-names></name>
        <name><surname>Seng</surname><given-names>Michael</given-names></name>
        <name><surname>Abbadi</surname><given-names>Sara</given-names></name>
        <name><surname>Schiapparelli</surname><given-names>Paula</given-names></name>
        <name><surname>Sarabia-Estrada</surname><given-names>Rachel</given-names></name>
        <name><surname>Vescovi</surname><given-names>Angelo</given-names></name>
        <name><surname>Brem</surname><given-names>Henry</given-names></name>
        <name><surname>Olivi</surname><given-names>Alessandro</given-names></name>
        <name><surname>Tyler</surname><given-names>Betty</given-names></name>
        <name><surname>Green</surname><given-names>Jordan J.</given-names></name>
        <name><surname>Quinones-Hinojosa</surname><given-names>Alfredo</given-names></name>
      </person-group>
      <article-title>Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival</article-title>
      <source>Biomaterials</source>
      <year iso-8601-date="2016-09">2016</year><month>09</month>
      <volume>100</volume>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S0142961216301983</uri>
      <pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.05.025</pub-id>
      <fpage>53</fpage>
      <lpage>66</lpage>
    </element-citation>
  </ref>
  <ref id="ref-chaichana2014">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Chaichana</surname><given-names>Kaisorn L.</given-names></name>
        <name><surname>Cabrera-Aldana</surname><given-names>Eibar Ernesto</given-names></name>
        <name><surname>Jusue-Torres</surname><given-names>Ignacio</given-names></name>
        <name><surname>Wijesekera</surname><given-names>Olindi</given-names></name>
        <name><surname>Olivi</surname><given-names>Alessandro</given-names></name>
        <name><surname>Rahman</surname><given-names>Maryam</given-names></name>
        <name><surname>Quinones-Hinojosa</surname><given-names>Alfredo</given-names></name>
      </person-group>
      <article-title>When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved?</article-title>
      <source>World Neurosurgery</source>
      <year iso-8601-date="2014-07">2014</year><month>07</month>
      <volume>82</volume>
      <issue>1-2</issue>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S1878875014000837</uri>
      <pub-id pub-id-type="doi">10.1016/j.wneu.2014.01.019</pub-id>
      <fpage>e257</fpage>
      <lpage>e265</lpage>
    </element-citation>
  </ref>
  <ref id="ref-mcmahon2018">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>McMahon</surname><given-names>Stephen Joseph</given-names></name>
      </person-group>
      <article-title>The linear quadratic model: Usage, interpretation and challenges</article-title>
      <source>Physics in Medicine &amp; Biology</source>
      <year iso-8601-date="2018-12-19">2018</year><month>12</month><day>19</day>
      <volume>64</volume>
      <issue>1</issue>
      <uri>https://iopscience.iop.org/article/10.1088/1361-6560/aaf26a</uri>
      <pub-id pub-id-type="doi">10.1088/1361-6560/aaf26a</pub-id>
      <fpage>01TR01</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-orourke2009">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>O’Rourke</surname><given-names>S. F. C.</given-names></name>
        <name><surname>McAneney</surname><given-names>H.</given-names></name>
        <name><surname>Hillen</surname><given-names>T.</given-names></name>
      </person-group>
      <article-title>Linear quadratic and tumour control probability modelling in external beam radiotherapy</article-title>
      <source>Journal of Mathematical Biology</source>
      <year iso-8601-date="2009-04">2009</year><month>04</month>
      <volume>58</volume>
      <issue>4-5</issue>
      <uri>http://link.springer.com/10.1007/s00285-008-0222-y</uri>
      <pub-id pub-id-type="doi">10.1007/s00285-008-0222-y</pub-id>
      <fpage>799</fpage>
      <lpage>817</lpage>
    </element-citation>
  </ref>
  <ref id="ref-bao2006">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Bao</surname><given-names>Shideng</given-names></name>
        <name><surname>Wu</surname><given-names>Qiulian</given-names></name>
        <name><surname>McLendon</surname><given-names>Roger E.</given-names></name>
        <name><surname>Hao</surname><given-names>Yueling</given-names></name>
        <name><surname>Shi</surname><given-names>Qing</given-names></name>
        <name><surname>Hjelmeland</surname><given-names>Anita B.</given-names></name>
        <name><surname>Dewhirst</surname><given-names>Mark W.</given-names></name>
        <name><surname>Bigner</surname><given-names>Darell D.</given-names></name>
        <name><surname>Rich</surname><given-names>Jeremy N.</given-names></name>
      </person-group>
      <article-title>Glioma stem cells promote radioresistance by preferential activation of the DNA damage response</article-title>
      <source>Nature</source>
      <year iso-8601-date="2006-12">2006</year><month>12</month>
      <volume>444</volume>
      <issue>7120</issue>
      <uri>https://www.nature.com/articles/nature05236</uri>
      <pub-id pub-id-type="doi">10.1038/nature05236</pub-id>
      <fpage>756</fpage>
      <lpage>760</lpage>
    </element-citation>
  </ref>
  <ref id="ref-griffin2006">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Griffin</surname><given-names>Robert J.</given-names></name>
      </person-group>
      <article-title>Radiobiology for the Radiologist, 6th Edition</article-title>
      <source>International Journal of Radiation Oncology*Biology*Physics</source>
      <year iso-8601-date="2006-10">2006</year><month>10</month>
      <volume>66</volume>
      <issue>2</issue>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S0360301606011242</uri>
      <pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.06.027</pub-id>
      <fpage>627</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-potten1981">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Potten</surname><given-names>C. S.</given-names></name>
      </person-group>
      <article-title>The Cell Kinetic Mechanism for Radiation-induced Cellular Depletion of Epithelial Tissue Based on Hierarchical Differences in Radiosensitivity</article-title>
      <source>International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine</source>
      <year iso-8601-date="1981-01">1981</year><month>01</month>
      <volume>40</volume>
      <issue>2</issue>
      <uri>http://www.tandfonline.com/doi/full/10.1080/09553008114551101</uri>
      <pub-id pub-id-type="doi">10.1080/09553008114551101</pub-id>
      <fpage>217</fpage>
      <lpage>225</lpage>
    </element-citation>
  </ref>
  <ref id="ref-tang2021">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Tang</surname><given-names>Xuejia</given-names></name>
        <name><surname>Zuo</surname><given-names>Chenghai</given-names></name>
        <name><surname>Fang</surname><given-names>Pengchao</given-names></name>
        <name><surname>Liu</surname><given-names>Guojing</given-names></name>
        <name><surname>Qiu</surname><given-names>Yongyi</given-names></name>
        <name><surname>Huang</surname><given-names>Yi</given-names></name>
        <name><surname>Tang</surname><given-names>Rongrui</given-names></name>
      </person-group>
      <article-title>Targeting glioblastoma stem cells: A review on biomarkers, signal pathways and targeted therapy</article-title>
      <source>Frontiers in Oncology</source>
      <year iso-8601-date="2021-07-08">2021</year><month>07</month><day>08</day>
      <volume>11</volume>
      <uri>https://www.frontiersin.org/articles/10.3389/fonc.2021.701291/full</uri>
      <pub-id pub-id-type="doi">10.3389/fonc.2021.701291</pub-id>
      <fpage>701291</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-rich2007">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Rich</surname><given-names>Jeremy N.</given-names></name>
      </person-group>
      <article-title>Cancer Stem Cells in Radiation Resistance</article-title>
      <source>Cancer Research</source>
      <year iso-8601-date="2007-10-01">2007</year><month>10</month><day>01</day>
      <volume>67</volume>
      <issue>19</issue>
      <uri>https://aacrjournals.org/cancerres/article/67/19/8980/533728/Cancer-Stem-Cells-in-Radiation-Resistance</uri>
      <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0895</pub-id>
      <fpage>8980</fpage>
      <lpage>8984</lpage>
    </element-citation>
  </ref>
  <ref id="ref-stiles2008">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Stiles</surname><given-names>Charles D.</given-names></name>
        <name><surname>Rowitch</surname><given-names>David H.</given-names></name>
      </person-group>
      <article-title>Glioma Stem Cells: A Midterm Exam</article-title>
      <source>Neuron</source>
      <year iso-8601-date="2008-06">2008</year><month>06</month>
      <volume>58</volume>
      <issue>6</issue>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S0896627308004947</uri>
      <pub-id pub-id-type="doi">10.1016/j.neuron.2008.05.031</pub-id>
      <fpage>832</fpage>
      <lpage>846</lpage>
    </element-citation>
  </ref>
  <ref id="ref-schonberg2014">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Schonberg</surname><given-names>David L.</given-names></name>
        <name><surname>Lubelski</surname><given-names>Daniel</given-names></name>
        <name><surname>Miller</surname><given-names>Tyler E.</given-names></name>
        <name><surname>Rich</surname><given-names>Jeremy N.</given-names></name>
      </person-group>
      <article-title>Brain tumor stem cells: Molecular characteristics and their impact on therapy</article-title>
      <source>Molecular Aspects of Medicine</source>
      <year iso-8601-date="2014-10">2014</year><month>10</month>
      <volume>39</volume>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S0098299713000447</uri>
      <pub-id pub-id-type="doi">10.1016/j.mam.2013.06.004</pub-id>
      <fpage>82</fpage>
      <lpage>101</lpage>
    </element-citation>
  </ref>
  <ref id="ref-ma2018">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Ma</surname><given-names>Qianquan</given-names></name>
        <name><surname>Long</surname><given-names>Wenyong</given-names></name>
        <name><surname>Xing</surname><given-names>Changsheng</given-names></name>
        <name><surname>Chu</surname><given-names>Junjun</given-names></name>
        <name><surname>Luo</surname><given-names>Mei</given-names></name>
        <name><surname>Wang</surname><given-names>Helen Y.</given-names></name>
        <name><surname>Liu</surname><given-names>Qing</given-names></name>
        <name><surname>Wang</surname><given-names>Rong-Fu</given-names></name>
      </person-group>
      <article-title>Cancer stem cells and immunosuppressive microenvironment in glioma</article-title>
      <source>Frontiers in Immunology</source>
      <year iso-8601-date="2018-12-21">2018</year><month>12</month><day>21</day>
      <volume>9</volume>
      <uri>https://www.frontiersin.org/article/10.3389/fimmu.2018.02924/full</uri>
      <pub-id pub-id-type="doi">10.3389/fimmu.2018.02924</pub-id>
      <fpage>2924</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-dingli2006">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Dingli</surname><given-names>David</given-names></name>
        <name><surname>Michor</surname><given-names>Franziska</given-names></name>
      </person-group>
      <article-title>Successful Therapy Must Eradicate Cancer Stem Cells</article-title>
      <source>STEM CELLS</source>
      <year iso-8601-date="2006-12">2006</year><month>12</month>
      <volume>24</volume>
      <issue>12</issue>
      <uri>https://academic.oup.com/stmcls/article/24/12/2603-2610/6401754</uri>
      <pub-id pub-id-type="doi">10.1634/stemcells.2006-0136</pub-id>
      <fpage>2603</fpage>
      <lpage>2610</lpage>
    </element-citation>
  </ref>
  <ref id="ref-bachman2013">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Bachman</surname><given-names>Jeff W. N.</given-names></name>
        <name><surname>Hillen</surname><given-names>Thomas</given-names></name>
      </person-group>
      <article-title>Mathematical optimization of the combination of radiation and differentiation therapies for cancer</article-title>
      <source>Frontiers in Oncology</source>
      <year iso-8601-date="2013">2013</year>
      <volume>3</volume>
      <uri>http://journal.frontiersin.org/article/10.3389/fonc.2013.00052/abstract</uri>
      <pub-id pub-id-type="doi">10.3389/fonc.2013.00052</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-lee2016">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Lee</surname><given-names>Yeri</given-names></name>
        <name><surname>Lee</surname><given-names>Jin-Ku</given-names></name>
        <name><surname>Ahn</surname><given-names>Sun Hee</given-names></name>
        <name><surname>Lee</surname><given-names>Jeongwu</given-names></name>
        <name><surname>Nam</surname><given-names>Do-Hyun</given-names></name>
      </person-group>
      <article-title>WNT signaling in glioblastoma and therapeutic opportunities</article-title>
      <source>Laboratory Investigation</source>
      <year iso-8601-date="2016-02">2016</year><month>02</month>
      <volume>96</volume>
      <issue>2</issue>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S0023683722023029</uri>
      <pub-id pub-id-type="doi">10.1038/labinvest.2015.140</pub-id>
      <fpage>137</fpage>
      <lpage>150</lpage>
    </element-citation>
  </ref>
  <ref id="ref-yang2019">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Yang</surname><given-names>Wei</given-names></name>
        <name><surname>Warrington</surname><given-names>Nicole M.</given-names></name>
        <name><surname>Taylor</surname><given-names>Sara J.</given-names></name>
        <name><surname>Whitmire</surname><given-names>Paula</given-names></name>
        <name><surname>Carrasco</surname><given-names>Eduardo</given-names></name>
        <name><surname>Singleton</surname><given-names>Kyle W.</given-names></name>
        <name><surname>Wu</surname><given-names>Ningying</given-names></name>
        <name><surname>Lathia</surname><given-names>Justin D.</given-names></name>
        <name><surname>Berens</surname><given-names>Michael E.</given-names></name>
        <name><surname>Kim</surname><given-names>Albert H.</given-names></name>
        <name><surname>Barnholtz-Sloan</surname><given-names>Jill S.</given-names></name>
        <name><surname>Swanson</surname><given-names>Kristin R.</given-names></name>
        <name><surname>Luo</surname><given-names>Jingqin</given-names></name>
        <name><surname>Rubin</surname><given-names>Joshua B.</given-names></name>
      </person-group>
      <article-title>Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data</article-title>
      <source>Science Translational Medicine</source>
      <year iso-8601-date="2019-01-02">2019</year><month>01</month><day>02</day>
      <volume>11</volume>
      <issue>473</issue>
      <uri>https://www.science.org/doi/10.1126/scitranslmed.aao5253</uri>
      <pub-id pub-id-type="doi">10.1126/scitranslmed.aao5253</pub-id>
      <fpage>eaao5253</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-lapidot1994">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Lapidot</surname><given-names>Tsvee</given-names></name>
        <name><surname>Sirard</surname><given-names>Christian</given-names></name>
        <name><surname>Vormoor</surname><given-names>Josef</given-names></name>
        <name><surname>Murdoch</surname><given-names>Barbara</given-names></name>
        <name><surname>Hoang</surname><given-names>Trang</given-names></name>
        <name><surname>Caceres-Cortes</surname><given-names>Julio</given-names></name>
        <name><surname>Minden</surname><given-names>Mark</given-names></name>
        <name><surname>Paterson</surname><given-names>Bruce</given-names></name>
        <name><surname>Caligiuri</surname><given-names>Michael A.</given-names></name>
        <name><surname>Dick</surname><given-names>John E.</given-names></name>
      </person-group>
      <article-title>A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</article-title>
      <source>Nature</source>
      <year iso-8601-date="1994-02">1994</year><month>02</month>
      <volume>367</volume>
      <issue>6464</issue>
      <uri>https://www.nature.com/articles/367645a0</uri>
      <pub-id pub-id-type="doi">10.1038/367645a0</pub-id>
      <fpage>645</fpage>
      <lpage>648</lpage>
    </element-citation>
  </ref>
  <ref id="ref-bonnet1997">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Bonnet</surname><given-names>Dominique</given-names></name>
        <name><surname>Dick</surname><given-names>John E.</given-names></name>
      </person-group>
      <article-title>Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell</article-title>
      <source>Nature Medicine</source>
      <year iso-8601-date="1997-07">1997</year><month>07</month>
      <volume>3</volume>
      <issue>7</issue>
      <uri>https://www.nature.com/articles/nm0797-730</uri>
      <pub-id pub-id-type="doi">10.1038/nm0797-730</pub-id>
      <fpage>730</fpage>
      <lpage>737</lpage>
    </element-citation>
  </ref>
  <ref id="ref-al-hajj2003">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Al-Hajj</surname><given-names>Muhammad</given-names></name>
        <name><surname>Wicha</surname><given-names>Max S.</given-names></name>
        <name><surname>Benito-Hernandez</surname><given-names>Adalberto</given-names></name>
        <name><surname>Morrison</surname><given-names>Sean J.</given-names></name>
        <name><surname>Clarke</surname><given-names>Michael F.</given-names></name>
      </person-group>
      <article-title>Prospective identification of tumorigenic breast cancer cells</article-title>
      <source>Proceedings of the National Academy of Sciences</source>
      <year iso-8601-date="2003-04">2003</year><month>04</month>
      <volume>100</volume>
      <issue>7</issue>
      <uri>https://pnas.org/doi/full/10.1073/pnas.0530291100</uri>
      <pub-id pub-id-type="doi">10.1073/pnas.0530291100</pub-id>
      <fpage>3983</fpage>
      <lpage>3988</lpage>
    </element-citation>
  </ref>
  <ref id="ref-ricci-vitiani2007">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Ricci-Vitiani</surname><given-names>Lucia</given-names></name>
        <name><surname>Lombardi</surname><given-names>Dario G.</given-names></name>
        <name><surname>Pilozzi</surname><given-names>Emanuela</given-names></name>
        <name><surname>Biffoni</surname><given-names>Mauro</given-names></name>
        <name><surname>Todaro</surname><given-names>Matilde</given-names></name>
        <name><surname>Peschle</surname><given-names>Cesare</given-names></name>
        <name><surname>De Maria</surname><given-names>Ruggero</given-names></name>
      </person-group>
      <article-title>Identification and expansion of human colon-cancer-initiating cells</article-title>
      <source>Nature</source>
      <year iso-8601-date="2007-01">2007</year><month>01</month>
      <volume>445</volume>
      <issue>7123</issue>
      <uri>https://www.nature.com/articles/nature05384</uri>
      <pub-id pub-id-type="doi">10.1038/nature05384</pub-id>
      <fpage>111</fpage>
      <lpage>115</lpage>
    </element-citation>
  </ref>
  <ref id="ref-ignatova2002">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Ignatova</surname><given-names>Tatyana N.</given-names></name>
        <name><surname>Kukekov</surname><given-names>Valery G.</given-names></name>
        <name><surname>Laywell</surname><given-names>Eric D.</given-names></name>
        <name><surname>Suslov</surname><given-names>Oleg N.</given-names></name>
        <name><surname>Vrionis</surname><given-names>Frank D.</given-names></name>
        <name><surname>Steindler</surname><given-names>Dennis A.</given-names></name>
      </person-group>
      <article-title>Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro</article-title>
      <source>Glia</source>
      <year iso-8601-date="2002-09">2002</year><month>09</month>
      <volume>39</volume>
      <issue>3</issue>
      <uri>https://onlinelibrary.wiley.com/doi/10.1002/glia.10094</uri>
      <pub-id pub-id-type="doi">10.1002/glia.10094</pub-id>
      <fpage>193</fpage>
      <lpage>206</lpage>
    </element-citation>
  </ref>
  <ref id="ref-hemmati2003">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Hemmati</surname><given-names>Houman D.</given-names></name>
        <name><surname>Nakano</surname><given-names>Ichiro</given-names></name>
        <name><surname>Lazareff</surname><given-names>Jorge A.</given-names></name>
        <name><surname>Masterman-Smith</surname><given-names>Michael</given-names></name>
        <name><surname>Geschwind</surname><given-names>Daniel H.</given-names></name>
        <name><surname>Bronner-Fraser</surname><given-names>Marianne</given-names></name>
        <name><surname>Kornblum</surname><given-names>Harley I.</given-names></name>
      </person-group>
      <article-title>Cancerous stem cells can arise from pediatric brain tumors</article-title>
      <source>Proceedings of the National Academy of Sciences</source>
      <year iso-8601-date="2003-12-09">2003</year><month>12</month><day>09</day>
      <volume>100</volume>
      <issue>25</issue>
      <uri>https://pnas.org/doi/full/10.1073/pnas.2036535100</uri>
      <pub-id pub-id-type="doi">10.1073/pnas.2036535100</pub-id>
      <fpage>15178</fpage>
      <lpage>15183</lpage>
    </element-citation>
  </ref>
  <ref id="ref-galli2004">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Galli</surname><given-names>Rossella</given-names></name>
        <name><surname>Binda</surname><given-names>Elena</given-names></name>
        <name><surname>Orfanelli</surname><given-names>Ugo</given-names></name>
        <name><surname>Cipelletti</surname><given-names>Barbara</given-names></name>
        <name><surname>Gritti</surname><given-names>Angela</given-names></name>
        <name><surname>De Vitis</surname><given-names>Simona</given-names></name>
        <name><surname>Fiocco</surname><given-names>Roberta</given-names></name>
        <name><surname>Foroni</surname><given-names>Chiara</given-names></name>
        <name><surname>Dimeco</surname><given-names>Francesco</given-names></name>
        <name><surname>Vescovi</surname><given-names>Angelo</given-names></name>
      </person-group>
      <article-title>Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma</article-title>
      <source>Cancer Research</source>
      <year iso-8601-date="2004-10-01">2004</year><month>10</month><day>01</day>
      <volume>64</volume>
      <issue>19</issue>
      <uri>https://aacrjournals.org/cancerres/article/64/19/7011/511722/Isolation-and-Characterization-of-Tumorigenic-Stem</uri>
      <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1364</pub-id>
      <fpage>7011</fpage>
      <lpage>7021</lpage>
    </element-citation>
  </ref>
  <ref id="ref-carén2016">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Carén</surname><given-names>Helena</given-names></name>
        <name><surname>Beck</surname><given-names>Stephan</given-names></name>
        <name><surname>Pollard</surname><given-names>Steven M.</given-names></name>
      </person-group>
      <article-title>Differentiation therapy for glioblastoma  too many obstacles?</article-title>
      <source>Molecular &amp; Cellular Oncology</source>
      <year iso-8601-date="2016-03-03">2016</year><month>03</month><day>03</day>
      <volume>3</volume>
      <issue>2</issue>
      <uri>https://www.tandfonline.com/doi/full/10.1080/23723556.2015.1124174</uri>
      <pub-id pub-id-type="doi">10.1080/23723556.2015.1124174</pub-id>
      <fpage>e1124174</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-dethé2018">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>De Thé</surname><given-names>Hugues</given-names></name>
      </person-group>
      <article-title>Differentiation therapy revisited</article-title>
      <source>Nature Reviews Cancer</source>
      <year iso-8601-date="2018-02">2018</year><month>02</month>
      <volume>18</volume>
      <issue>2</issue>
      <uri>https://www.nature.com/articles/nrc.2017.103</uri>
      <pub-id pub-id-type="doi">10.1038/nrc.2017.103</pub-id>
      <fpage>117</fpage>
      <lpage>127</lpage>
    </element-citation>
  </ref>
  <ref id="ref-yan2016">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Yan</surname><given-names>Min</given-names></name>
        <name><surname>Liu</surname><given-names>Quentin</given-names></name>
      </person-group>
      <article-title>Differentiation therapy: a promising strategy for cancer treatment</article-title>
      <source>Chinese Journal of Cancer</source>
      <year iso-8601-date="2016-12">2016</year><month>12</month>
      <volume>35</volume>
      <issue>1</issue>
      <uri>https://cancercommun.biomedcentral.com/articles/10.1186/s40880-015-0059-x</uri>
      <pub-id pub-id-type="doi">10.1186/s40880-015-0059-x</pub-id>
      <fpage>3</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-nayak2020">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Nayak</surname><given-names>Sonali</given-names></name>
        <name><surname>Mahenthiran</surname><given-names>Ashorne</given-names></name>
        <name><surname>Yang</surname><given-names>Yongyong</given-names></name>
        <name><surname>McClendon</surname><given-names>Mark</given-names></name>
        <name><surname>Mania-Farnell</surname><given-names>Barbara</given-names></name>
        <name><surname>James</surname><given-names>Charles David</given-names></name>
        <name><surname>Kessler</surname><given-names>John A.</given-names></name>
        <name><surname>Tomita</surname><given-names>Tadanori</given-names></name>
        <name><surname>Cheng</surname><given-names>Shi-Yuan</given-names></name>
        <name><surname>Stupp</surname><given-names>Samuel I.</given-names></name>
        <name><surname>Xi</surname><given-names>Guifa</given-names></name>
      </person-group>
      <article-title>Bone Morphogenetic Protein 4 Targeting Glioma Stem-Like Cells for Malignant Glioma Treatment: Latest Advances and Implications for Clinical Application</article-title>
      <source>Cancers</source>
      <year iso-8601-date="2020-02-24">2020</year><month>02</month><day>24</day>
      <volume>12</volume>
      <issue>2</issue>
      <uri>https://www.mdpi.com/2072-6694/12/2/516</uri>
      <pub-id pub-id-type="doi">10.3390/cancers12020516</pub-id>
      <fpage>516</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-guerrero-cázares2014">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Guerrero-Cázares</surname><given-names>Hugo</given-names></name>
        <name><surname>Tzeng</surname><given-names>Stephany Y.</given-names></name>
        <name><surname>Young</surname><given-names>Noah P.</given-names></name>
        <name><surname>Abutaleb</surname><given-names>Ameer O.</given-names></name>
        <name><surname>Quiñones-Hinojosa</surname><given-names>Alfredo</given-names></name>
        <name><surname>Green</surname><given-names>Jordan J.</given-names></name>
      </person-group>
      <article-title>Biodegradable Polymeric Nanoparticles Show High Efficacy and Specificity at DNA Delivery to Human Glioblastoma in Vitro and in Vivo</article-title>
      <source>ACS Nano</source>
      <year iso-8601-date="2014-05-27">2014</year><month>05</month><day>27</day>
      <volume>8</volume>
      <issue>5</issue>
      <uri>https://pubs.acs.org/doi/10.1021/nn501197v</uri>
      <pub-id pub-id-type="doi">10.1021/nn501197v</pub-id>
      <fpage>5141</fpage>
      <lpage>5153</lpage>
    </element-citation>
  </ref>
  <ref id="ref-li2014">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Li</surname><given-names>Qian</given-names></name>
        <name><surname>Wijesekera</surname><given-names>Olindi</given-names></name>
        <name><surname>Salas</surname><given-names>Sussan J.</given-names></name>
        <name><surname>Wang</surname><given-names>Joanna Y.</given-names></name>
        <name><surname>Zhu</surname><given-names>Mingxin</given-names></name>
        <name><surname>Aprhys</surname><given-names>Colette</given-names></name>
        <name><surname>Chaichana</surname><given-names>Kaisorn L.</given-names></name>
        <name><surname>Chesler</surname><given-names>David A.</given-names></name>
        <name><surname>Zhang</surname><given-names>Hao</given-names></name>
        <name><surname>Smith</surname><given-names>Christopher L.</given-names></name>
        <name><surname>Guerrero-Cazares</surname><given-names>Hugo</given-names></name>
        <name><surname>Levchenko</surname><given-names>Andre</given-names></name>
        <name><surname>Quinones-Hinojosa</surname><given-names>Alfredo</given-names></name>
      </person-group>
      <article-title>Mesenchymal Stem Cells from Human Fat Engineered to Secrete BMP4 Are Nononcogenic, Suppress Brain Cancer, and Prolong Survival</article-title>
      <source>Clinical Cancer Research</source>
      <year iso-8601-date="2014-05-01">2014</year><month>05</month><day>01</day>
      <volume>20</volume>
      <issue>9</issue>
      <uri>https://aacrjournals.org/clincancerres/article/20/9/2375/78818/Mesenchymal-Stem-Cells-from-Human-Fat-Engineered</uri>
      <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1415</pub-id>
      <fpage>2375</fpage>
      <lpage>2387</lpage>
    </element-citation>
  </ref>
  <ref id="ref-pendleton2013">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Pendleton</surname><given-names>Courtney</given-names></name>
        <name><surname>Li</surname><given-names>Qian</given-names></name>
        <name><surname>Chesler</surname><given-names>David A.</given-names></name>
        <name><surname>Yuan</surname><given-names>Kristy</given-names></name>
        <name><surname>Guerrero-Cazares</surname><given-names>Hugo</given-names></name>
        <name><surname>Quinones-Hinojosa</surname><given-names>Alfredo</given-names></name>
      </person-group>
      <article-title>Mesenchymal Stem Cells Derived from Adipose Tissue vs Bone Marrow: In Vitro Comparison of Their Tropism towards Gliomas</article-title>
      <source>PLoS ONE</source>
      <person-group person-group-type="editor">
        <name><surname>Najbauer</surname><given-names>Joseph</given-names></name>
      </person-group>
      <year iso-8601-date="2013-03-12">2013</year><month>03</month><day>12</day>
      <volume>8</volume>
      <issue>3</issue>
      <uri>https://dx.plos.org/10.1371/journal.pone.0058198</uri>
      <pub-id pub-id-type="doi">10.1371/journal.pone.0058198</pub-id>
      <fpage>e58198</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-smith2015">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Smith</surname><given-names>Chris L.</given-names></name>
        <name><surname>Chaichana</surname><given-names>Kaisorn L.</given-names></name>
        <name><surname>Lee</surname><given-names>Young M.</given-names></name>
        <name><surname>Lin</surname><given-names>Benjamin</given-names></name>
        <name><surname>Stanko</surname><given-names>Kevin M.</given-names></name>
        <name><surname>O’Donnell</surname><given-names>Thomas</given-names></name>
        <name><surname>Gupta</surname><given-names>Saksham</given-names></name>
        <name><surname>Shah</surname><given-names>Sagar R.</given-names></name>
        <name><surname>Wang</surname><given-names>Joanne</given-names></name>
        <name><surname>Wijesekera</surname><given-names>Olindi</given-names></name>
        <name><surname>Delannoy</surname><given-names>Michael</given-names></name>
        <name><surname>Levchenko</surname><given-names>Andre</given-names></name>
        <name><surname>Quiñones-Hinojosa</surname><given-names>Alfredo</given-names></name>
      </person-group>
      <article-title>Pre-Exposure of Human Adipose Mesenchymal Stem Cells to Soluble Factors Enhances Their Homing to Brain Cancer</article-title>
      <source>Stem Cells Translational Medicine</source>
      <year iso-8601-date="2015-03-01">2015</year><month>03</month><day>01</day>
      <volume>4</volume>
      <issue>3</issue>
      <uri>https://academic.oup.com/stcltm/article/4/3/239-251/6397303</uri>
      <pub-id pub-id-type="doi">10.5966/sctm.2014-0149</pub-id>
      <fpage>239</fpage>
      <lpage>251</lpage>
    </element-citation>
  </ref>
  <ref id="ref-doucette2011">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Doucette</surname><given-names>Tiffany</given-names></name>
        <name><surname>Rao</surname><given-names>Ganesh</given-names></name>
        <name><surname>Yang</surname><given-names>Yuhui</given-names></name>
        <name><surname>Gumin</surname><given-names>Joy</given-names></name>
        <name><surname>Shinojima</surname><given-names>Naoki</given-names></name>
        <name><surname>Bekele</surname><given-names>B. Nebiyou</given-names></name>
        <name><surname>Qiao</surname><given-names>Wei</given-names></name>
        <name><surname>Zhang</surname><given-names>Wei</given-names></name>
        <name><surname>Lang</surname><given-names>Frederick F.</given-names></name>
      </person-group>
      <article-title>Mesenchymal Stem Cells Display Tumor-Specific Tropism in an RCAS/Ntv-a Glioma Model</article-title>
      <source>Neoplasia</source>
      <year iso-8601-date="2011-08">2011</year><month>08</month>
      <volume>13</volume>
      <issue>8</issue>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S1476558611800060</uri>
      <pub-id pub-id-type="doi">10.1593/neo.101680</pub-id>
      <fpage>716</fpage>
      <lpage>725</lpage>
    </element-citation>
  </ref>
  <ref id="ref-kim2020">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Kim</surname><given-names>Jayoung</given-names></name>
        <name><surname>Mondal</surname><given-names>Sujan K.</given-names></name>
        <name><surname>Tzeng</surname><given-names>Stephany Y.</given-names></name>
        <name><surname>Rui</surname><given-names>Yuan</given-names></name>
        <name><surname>Al-kharboosh</surname><given-names>Rawan</given-names></name>
        <name><surname>Kozielski</surname><given-names>Kristen K.</given-names></name>
        <name><surname>Bhargav</surname><given-names>Adip G.</given-names></name>
        <name><surname>Garcia</surname><given-names>Cesar A.</given-names></name>
        <name><surname>Quiñones-Hinojosa</surname><given-names>Alfredo</given-names></name>
        <name><surname>Green</surname><given-names>Jordan J.</given-names></name>
      </person-group>
      <article-title>Poly(ethylene glycol)Poly(beta-amino ester)-Based Nanoparticles for Suicide Gene Therapy Enhance Brain Penetration and Extend Survival in a Preclinical Human Glioblastoma Orthotopic Xenograft Model</article-title>
      <source>ACS Biomaterials Science &amp; Engineering</source>
      <year iso-8601-date="2020-05-11">2020</year><month>05</month><day>11</day>
      <volume>6</volume>
      <issue>5</issue>
      <uri>https://pubs.acs.org/doi/10.1021/acsbiomaterials.0c00116</uri>
      <pub-id pub-id-type="doi">10.1021/acsbiomaterials.0c00116</pub-id>
      <fpage>2943</fpage>
      <lpage>2955</lpage>
    </element-citation>
  </ref>
  <ref id="ref-tzeng2011">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Tzeng</surname><given-names>Stephany Y.</given-names></name>
        <name><surname>Guerrero-Cázares</surname><given-names>Hugo</given-names></name>
        <name><surname>Martinez</surname><given-names>Elliott E.</given-names></name>
        <name><surname>Sunshine</surname><given-names>Joel C.</given-names></name>
        <name><surname>Quiñones-Hinojosa</surname><given-names>Alfredo</given-names></name>
        <name><surname>Green</surname><given-names>Jordan J.</given-names></name>
      </person-group>
      <article-title>Non-viral gene delivery nanoparticles based on Poly(beta-amino esters) for treatment of glioblastoma</article-title>
      <source>Biomaterials</source>
      <year iso-8601-date="2011-08">2011</year><month>08</month>
      <volume>32</volume>
      <issue>23</issue>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S014296121100398X</uri>
      <pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.04.016</pub-id>
      <fpage>5402</fpage>
      <lpage>5410</lpage>
    </element-citation>
  </ref>
  <ref id="ref-yu2015">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Yu</surname><given-names>Victoria Y.</given-names></name>
        <name><surname>Nguyen</surname><given-names>Dan</given-names></name>
        <name><surname>Pajonk</surname><given-names>Frank</given-names></name>
        <name><surname>Kupelian</surname><given-names>Patrick</given-names></name>
        <name><surname>Kaprealian</surname><given-names>Tania</given-names></name>
        <name><surname>Selch</surname><given-names>Michael</given-names></name>
        <name><surname>Low</surname><given-names>Daniel A.</given-names></name>
        <name><surname>Sheng</surname><given-names>Ke</given-names></name>
      </person-group>
      <article-title>Incorporating Cancer Stem Cells in Radiation Therapy Treatment Response Modeling and the Implication in Glioblastoma Multiforme Treatment Resistance</article-title>
      <source>International Journal of Radiation Oncology*Biology*Physics</source>
      <year iso-8601-date="2015-03">2015</year><month>03</month>
      <volume>91</volume>
      <issue>4</issue>
      <uri>https://linkinghub.elsevier.com/retrieve/pii/S0360301614044605</uri>
      <pub-id pub-id-type="doi">10.1016/j.ijrobp.2014.12.004</pub-id>
      <fpage>866</fpage>
      <lpage>875</lpage>
    </element-citation>
  </ref>
  <ref id="ref-farias">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Farias</surname><given-names>Virgina</given-names></name>
        <name><surname>Rani</surname><given-names>Vinitha</given-names></name>
        <name><surname>Zacro</surname><given-names>Natanael</given-names></name>
        <name><surname>Brooks</surname><given-names>Mieu</given-names></name>
        <name><surname>Nagaiah</surname><given-names>Naveen</given-names></name>
        <name><surname>Ruiz-Garcia</surname><given-names>Henry</given-names></name>
        <name><surname>Sarabia-Estrada</surname><given-names>Rachel</given-names></name>
        <name><surname>Forte</surname><given-names>Antonio</given-names></name>
        <name><surname>Triffiletti</surname><given-names>Daniel</given-names></name>
        <name><surname>Guerrero-Cazares</surname><given-names>Hugo</given-names></name>
        <name><surname>Rosenfeld</surname><given-names>Steven</given-names></name>
        <name><surname>Kenchappa</surname><given-names>Rajappa</given-names></name>
        <name><surname>Quinones-Hinojosa</surname><given-names>Alfredo</given-names></name>
      </person-group>
      <article-title>BMP4-secreting MSCs derived from human adipose tissue radiosensitize glioblastoma stem cells via downregulation of OLIG2 signaling pathway.</article-title>
      <source>In preparation</source>
    </element-citation>
  </ref>
  <ref id="ref-craig2023">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Craig</surname><given-names>Morgan</given-names></name>
        <name><surname>Gevertz</surname><given-names>Jana L.</given-names></name>
        <name><surname>Kareva</surname><given-names>Irina</given-names></name>
        <name><surname>Wilkie</surname><given-names>Kathleen P.</given-names></name>
      </person-group>
      <article-title>A practical guide for the generation of model-based virtual clinical trials</article-title>
      <source>Frontiers in Systems Biology</source>
      <year iso-8601-date="2023-06-16">2023</year><month>06</month><day>16</day>
      <volume>3</volume>
      <uri>http://dx.doi.org/10.3389/fsysb.2023.1174647</uri>
      <pub-id pub-id-type="doi">10.3389/fsysb.2023.1174647</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-wu2022">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Wu</surname><given-names>Chengyue</given-names></name>
        <name><surname>Lorenzo</surname><given-names>Guillermo</given-names></name>
        <name><surname>Hormuth</surname><given-names>David A.</given-names></name>
        <name><surname>Lima</surname><given-names>Ernesto A. B. F.</given-names></name>
        <name><surname>Slavkova</surname><given-names>Kalina P.</given-names></name>
        <name><surname>DiCarlo</surname><given-names>Julie C.</given-names></name>
        <name><surname>Virostko</surname><given-names>John</given-names></name>
        <name><surname>Phillips</surname><given-names>Caleb M.</given-names></name>
        <name><surname>Patt</surname><given-names>Debra</given-names></name>
        <name><surname>Chung</surname><given-names>Caroline</given-names></name>
        <name><surname>Yankeelov</surname><given-names>Thomas E.</given-names></name>
      </person-group>
      <article-title>Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology</article-title>
      <source>Biophysics Reviews</source>
      <year iso-8601-date="2022-05-17">2022</year><month>05</month><day>17</day>
      <volume>3</volume>
      <issue>2</issue>
      <uri>http://dx.doi.org/10.1063/5.0086789</uri>
      <pub-id pub-id-type="doi">10.1063/5.0086789</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-wang2019">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Wang</surname><given-names>Hanwen</given-names></name>
        <name><surname>Milberg</surname><given-names>Oleg</given-names></name>
        <name><surname>Bartelink</surname><given-names>Imke H.</given-names></name>
        <name><surname>Vicini</surname><given-names>Paolo</given-names></name>
        <name><surname>Wang</surname><given-names>Bing</given-names></name>
        <name><surname>Narwal</surname><given-names>Rajesh</given-names></name>
        <name><surname>Roskos</surname><given-names>Lorin</given-names></name>
        <name><surname>Santa-Maria</surname><given-names>Cesar A.</given-names></name>
        <name><surname>Popel</surname><given-names>Aleksander S.</given-names></name>
      </person-group>
      <article-title>In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model</article-title>
      <source>Royal Society Open Science</source>
      <year iso-8601-date="2019-05">2019</year><month>05</month>
      <volume>6</volume>
      <issue>5</issue>
      <uri>http://dx.doi.org/10.1098/rsos.190366</uri>
      <pub-id pub-id-type="doi">10.1098/rsos.190366</pub-id>
      <fpage>190366</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-wang2020">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Wang</surname><given-names>Hanwen</given-names></name>
        <name><surname>Sové</surname><given-names>Richard J.</given-names></name>
        <name><surname>Jafarnejad</surname><given-names>Mohammad</given-names></name>
        <name><surname>Rahmeh</surname><given-names>Sondra</given-names></name>
        <name><surname>Jaffee</surname><given-names>Elizabeth M.</given-names></name>
        <name><surname>Stearns</surname><given-names>Vered</given-names></name>
        <name><surname>Torres</surname><given-names>Evanthia T. Roussos</given-names></name>
        <name><surname>Connolly</surname><given-names>Roisin M.</given-names></name>
        <name><surname>Popel</surname><given-names>Aleksander S.</given-names></name>
      </person-group>
      <article-title>Conducting a virtual clinical trial in HER2-negative breast cancer using a quantitative systems pharmacology model with an epigenetic modulator and immune checkpoint inhibitors</article-title>
      <source>Frontiers in Bioengineering and Biotechnology</source>
      <year iso-8601-date="2020-02-25">2020</year><month>02</month><day>25</day>
      <volume>8</volume>
      <uri>http://dx.doi.org/10.3389/fbioe.2020.00141</uri>
      <pub-id pub-id-type="doi">10.3389/fbioe.2020.00141</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-zahid2021">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Zahid</surname><given-names>Mohammad U.</given-names></name>
        <name><surname>Mohamed</surname><given-names>Abdallah S. R.</given-names></name>
        <name><surname>Caudell</surname><given-names>Jimmy J.</given-names></name>
        <name><surname>Harrison</surname><given-names>Louis B.</given-names></name>
        <name><surname>Fuller</surname><given-names>Clifton D.</given-names></name>
        <name><surname>Moros</surname><given-names>Eduardo G.</given-names></name>
        <name><surname>Enderling</surname><given-names>Heiko</given-names></name>
      </person-group>
      <article-title>Dynamics-Adapted Radiotherapy Dose (DARD) for Head and Neck Cancer Radiotherapy Dose Personalization</article-title>
      <source>Journal of Personalized Medicine</source>
      <year iso-8601-date="2021-11-01">2021</year><month>11</month><day>01</day>
      <volume>11</volume>
      <issue>11</issue>
      <uri>http://dx.doi.org/10.3390/jpm11111124</uri>
      <pub-id pub-id-type="doi">10.3390/jpm11111124</pub-id>
      <fpage>1124</fpage>
      <lpage></lpage>
    </element-citation>
  </ref>
  <ref id="ref-kim2016">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Kim</surname><given-names>Eunjung</given-names></name>
        <name><surname>Rebecca</surname><given-names>Vito W.</given-names></name>
        <name><surname>Smalley</surname><given-names>Keiran S. M.</given-names></name>
        <name><surname>Anderson</surname><given-names>Alexander R. A.</given-names></name>
      </person-group>
      <article-title>Phase i trials in melanoma: A framework to translate preclinical findings to the clinic</article-title>
      <source>European Journal of Cancer</source>
      <year iso-8601-date="2016-11">2016</year><month>11</month>
      <volume>67</volume>
      <uri>http://dx.doi.org/10.1016/j.ejca.2016.07.024</uri>
      <pub-id pub-id-type="doi">10.1016/j.ejca.2016.07.024</pub-id>
      <fpage>213</fpage>
      <lpage>222</lpage>
    </element-citation>
  </ref>
  <ref id="ref-cardinal2022">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Cardinal</surname><given-names>Olivia</given-names></name>
        <name><surname>Burlot</surname><given-names>Chloé</given-names></name>
        <name><surname>Fu</surname><given-names>Yangxin</given-names></name>
        <name><surname>Crosley</surname><given-names>Powel</given-names></name>
        <name><surname>Hitt</surname><given-names>Mary</given-names></name>
        <name><surname>Craig</surname><given-names>Morgan</given-names></name>
        <name><surname>Jenner</surname><given-names>Adrianne L.</given-names></name>
      </person-group>
      <article-title>Establishing combination PAC-1 and TRAIL regimens for treating ovarian cancer based on patient-specific pharmacokinetic profiles using in silico clinical trials</article-title>
      <source>Computational and Systems Oncology</source>
      <year iso-8601-date="2022-06">2022</year><month>06</month>
      <volume>2</volume>
      <issue>2</issue>
      <uri>http://dx.doi.org/10.1002/cso2.1035</uri>
      <pub-id pub-id-type="doi">10.1002/cso2.1035</pub-id>
    </element-citation>
  </ref>
  <ref id="ref-plevritis2006">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Plevritis</surname><given-names>Sylvia K.</given-names></name>
        <name><surname>Salzman</surname><given-names>Peter</given-names></name>
        <name><surname>Sigal</surname><given-names>Bronislava M.</given-names></name>
        <name><surname>Glynn</surname><given-names>Peter W.</given-names></name>
      </person-group>
      <article-title>A natural history model of stage progression applied to breast cancer</article-title>
      <source>Statistics in Medicine</source>
      <year iso-8601-date="2006-04-05">2006</year><month>04</month><day>05</day>
      <volume>26</volume>
      <issue>3</issue>
      <uri>http://dx.doi.org/10.1002/sim.2550</uri>
      <pub-id pub-id-type="doi">10.1002/sim.2550</pub-id>
      <fpage>581</fpage>
      <lpage>595</lpage>
    </element-citation>
  </ref>
  <ref id="ref-bartoszynski2001">
    <element-citation publication-type="article-journal">
      <person-group person-group-type="author">
        <name><surname>Bartoszyński</surname><given-names>Robert</given-names></name>
        <name><surname>Edler</surname><given-names>Lutz</given-names></name>
        <name><surname>Hanin</surname><given-names>Leonid</given-names></name>
        <name><surname>Kopp-Schneider</surname><given-names>Annette</given-names></name>
        <name><surname>Pavlova</surname><given-names>Lyudmila</given-names></name>
        <name><surname>Tsodikov</surname><given-names>Alexander</given-names></name>
        <name><surname>Zorin</surname><given-names>Alexander</given-names></name>
        <name><surname>Yakovlev</surname><given-names>Andrej Yu.</given-names></name>
      </person-group>
      <article-title>Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis</article-title>
      <source>Mathematical Biosciences</source>
      <year iso-8601-date="2001-06">2001</year><month>06</month>
      <volume>171</volume>
      <issue>2</issue>
      <uri>http://dx.doi.org/10.1016/S0025-5564(01)00058-X</uri>
      <pub-id pub-id-type="doi">10.1016/s0025-5564(01)00058-x</pub-id>
      <fpage>113</fpage>
      <lpage>142</lpage>
    </element-citation>
  </ref>
</ref-list>
</back>



</article>